e roche finance report f hoffmannla roche ltd finance report basel switzerland trademarks legally protected wwwrochecom x xxx xxxfinance brief key results sales core operating profit margin cer growth sales pharmaceuticals diagnostics group change sales mchf mchf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change mchf mchf chf cer net debt capitalisation ebt e quity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant currencies average rates year ended december core results core eps earnings per share exclude noncore items global restructuring charges amortisation impairment goodwill intangible assets allows transparent assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given therefinance brief roche roche group reported strong overall results challenging market core operating profit grew ahead sales core earnings per share increased constant exchange rates cer swiss franc weaker average rates major currencies notably us dollar japanese yen positive overall impact income statement cash flows expressed swiss francs sales group sales increased cer billion swiss francs growth swiss franc terms pharmaceuticals sales growth cer strong growth established new oncology products actemraroactemra rheumatoid arthritis pegasys virology partially offset continuing impacts generic competition continuing pressures prices particularly japan western europe diagnostics sales grew cer ahead market professional diagnostics tissue diagnostics major contributors operating results core operating profit increased cer billion swiss francs growth swiss franc terms sales growth productivity improvements cost savings various global restructuring plans offset higher operating costs investments key markets well impacts price pressure increased competition core operating margin increased percentage points research development expenditure remained broadly stable slight increase cer billion swiss francs core basis due strict portfolio prioritisation supporting development pipeline rd costs group sales ifrs operating results include noncore items billion swiss francs includes billion restructuring pharmaceuticals divisions research development organisation restructuring diagnostics divisions applied science diabetes care businesses nonoperating results net financial expenses increased billion swiss francs billion swiss francs lower interest expenses offset higher net foreign exchange losses higher losses debt redemptions net income ifrs net income increased cer billion swiss francs swiss franc terms strong core operating results offset higher restructuring charges higher effective tax rate core earnings per share increased constant currencies swiss francs cash flows operating free cash flow billion swiss francs cer due higher operating profit free cash flow billion swiss francs cer repayment debt ahead schedule notes bonds issued finance genentech transaction repaid end financial position net working capital increased cer reflecting higher levels inventories due launches growth key products higher safety stock levels increased demand key markets net debt position improved billion swiss francs billion swiss francs credit ratings strong moodys standard poors upgraded aa shareholder return dividends proposed increase represent th consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr representing combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements summary significant accounting policies ccounts receivable perating segment information current assets c hugai arketable securities financial income financing costs cash cash equivalents ncome taxes ccounts payable b usiness combinations accrued current liabilities global restructuring plans derivative financial instruments e mployee benefits provisions contingent liabilities pensions postemployment noncurrent liabilities benefits ebt employee stock options equity equity attributable roche shareholders compensation plans earnings per share nonvoting equity property plant equipment security g oodwill n oncontrolling interests ntangible assets statement cash flows ssociates r isk management financial longterm assets r elated parties nventories subsidiaries associates report roche management internal control financial reporting report statutory auditor consolidated financial statements report independent auditor internal control financial reporting multiyear overview supplementary information roche securities roche hol ding ltd basel financial statements notes financial statements appropriation available earnings report statutory auditor financial statements financial review roche group results sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf roche groups results reported growth core operating activities sales core operating profit constant exchange rates core operating margin percentage points sales volume increases notably us emerging markets china latin america offset pricing pressures many markets cost sales ratio improved percentage points sales driven continuing productivity improvements pharmaceuticals division operating costs held necessary levels support future development business notably research development increased slightly due portfolio prioritisation supporting development pipeline strong operating performance partially offset higher tax rate responsible increase core eps constant exchange rates operating free cash flow grew billion swiss francs sales first half group initiated number major restructuring initiatives position business future notably pharmaceuticals divisions research development organisation announcement closure nutley site us diagnostics division initiated global restructuring programmes applied science diabetes care business areas address longterm profitability focusing fewer businesses products consolidating operations net income ifrs basis increased billion swiss francs swiss francs strong operating result offset large restructuring costs sales pharmaceuticals division rose led growth oncology portfolio sales billion swiss francs key growth drivers herceptin mabtherarituxan avastin actemraroactemra zelboraf pegasys e key emerging markets showed growth led sales growth china diagnostics sales grew expanding divisions leading market position major growth areas professional diagnostics tissue diagnostics sales diabetes care applied science declined core operating profit increased pharmaceuticals division growing diagnostics division fell divisions showed increases marketing distribution costs driven investments new products key markets notably us china also increased costs factoring contributed towards improved cash collections especially southern europe bad debt expenses decreased compared group level profitability pharmaceuticals increased percentage points due sales growth decrease cost sales productivity improvements portfolio prioritisation research development diagnostics profitability declined percentage points mainly due pricing pressures diabetes care business roche group financial review roche finance report operating free cash flow billion swiss francs increase compared reflects continued strong underlying cash generation groups operations making necessary investments develop business increase free cash flow billion swiss francs average swiss franc weaker compared average rates major currencies notably us dollar japanese yen overall impact positive income statement cash flows expressed swiss francs compared results constant exchange rates income statement change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable r oche shareholders n oncontrolling interests diluted eps chf core results sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable r oche shareholders n oncontrolling interests core eps chf roche finance report roche group financial reviewsales sales increased constant exchange rates swiss francs us dollars billion swiss francs sales pharmaceuticals division rose herceptin mabtherarituxan avastin actemraroactemra zelboraf pegasys growing strongly avastin returned growth increase sales positive results partially offset continued decline bonvivaboniva cellcept sales generic erosion following patent expiry neorecormonepogin due competition biosimilars e key emerging market sales pharmaceuticals grew led growth china diagnostics division sales billion swiss francs increase constant exchange rates expanding leading market position major growth area professional diagnostics represents half divisions sales grew tissue diagnostics also showed strong growth diabetes care sales declined applied science sales divisional operating results pharmaceuticals diagnostics corporate group mchf mchf mchf mchf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operating free cash flow increase cer margin percentage point increase core operating results pharmaceuticals division division increased core operating profit constant exchange rates driven growth underlying business increase sales improved gross profit margin contained spending core research development costs remained broadly stable slight increase increase marketing distribution fall general administration diagnostics division core operating profit sales increase offset pricing pressures diabetes care business cost sales increased higher rate sales growth due pricing impacts increased placement costs following expansion worldwide installed instrument base research development marketing distribution costs kept line sales growth significant growth general administration costs base effect due release provision described division initiated global restructuring plans address longterm profitability applied science diabetes care business areas roche group financial review roche finance report global restructuring plans first half group initiated several major global restructuring plans notably reorganisation research development pharmaceuticals division address longterm profitability applied science diabetes care business areas global restructuring plans costs incurred millions chf pharma pharma rd diagnostics informatics plans total global restructuring costs e mployeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs includes closure nutley site associated infrastructure environmental remediation costs includes restructuring applied science diabetes care business areas includes operational excellence pharmaceuticals diagnostics dalcetrapib pharmaceuticals pharmaceuticals division research development reorganisation june group announced streamlining research development activities within pharmaceuticals division part plan us site nutley new jersey closed end reduction workforce approximately people research development activities currently undertaken nutley consolidated existing sites switzerland germany planned translational clinical research centre alexandria centre life science manhattan us resulting savings global site consolidation related infrastructure costs bundling support functions well shifts portfolio allow reallocation resources growing number clinical programmes costs million swiss francs incurred based latest estimates cost reorganisation amount million swiss francs provisions severance payments employeerelated costs net estimated pension curtailment gains charge million swiss francs recorded impairments property plant equipment nutley site addition restructuring costs environmental remediation costs million swiss francs booked based initial estimates additional remediation activities may needed nutley site sold impairment charges intangible assets million swiss francs recorded result portfolio prioritisation decisions linked reorganisation diagnostics division applied science diabetes care restructuring initiatives announced applied science diabetes care businesses include streamlining product portfolio consolidating research development activities increasing efficiency marketing distribution operations costs million swiss francs incurred relate employee termination site closure costs addition goodwill impairment charges million swiss francs incurred full writeoff goodwill nimblegen acquisition resulting decision exit microarray business part reorganisation applied science business area well million swiss francs impairment intangible assets business area pharmaceuticals division global informatics reorganisation costs million swiss francs incurred mainly consist severance payments employeerelated costs roche finance report roche group financial reviewother global restructuring plans costs million swiss francs incurred previously announced operational excellence programme mainly employeerelated costs sales force restructuring initiatives pharmaceuticals division employeerelated site closure costs diagnostics division sites burgdorf switzerland graz austria second quarter pharmaceuticals division initiated detailed review following announcement results second interim analysis dalcetrapib daloutcomes phase iii trial subsequent termination daloutcomes trial studies dalheart programme consequently restructuring costs million swiss francs incurred consisted remaining trial costs writeoffs inventories property plant equipment additionally million swiss francs expensed writeoff previously acquired intangible assets impairment goodwill intangible assets impairment charges goodwill intangible assets million swiss francs million swiss francs respectively approximately half incurred various global restructuring initiatives described addition unrelated global restructuring plans impairment charges million swiss francs recorded major elements amount charges million swiss francs following portfolio prioritisation decision pharmaceuticals division relates decision return global rights monoclonal antibody rg antiplgf mab alliance partners charges million swiss francs follow latest clinical data assessment project acquired part marcadia acquisition legal environmental settlements addition environmental remediation costs million swiss francs nutley site mentioned million swiss francs legal environmental costs recorded unrelated global restructuring plans include estimated additional remediation costs landfill site near grenzach germany previously used manufacturing operations closed years ago treasury taxation financial income billion swiss francs decrease mainly due foreign currency losses whereas devaluationrelated foreign exchange gains occurred venezuela financing costs billion swiss francs decrease interest costs lower constant exchange rates debt repaid core tax expenses increased billion swiss francs groups effective core tax rate increased compared mainly consequence higher percentage core profit contribution coming us relatively higher local tax rate average group rate net income earnings per share ifrs net income increased diluted eps strong core operating performance offset costs various global restructuring plans core basis excludes noncore items global restructuring costs amortisation impairment goodwill intangible assets net income core eps higher driven strong operating performance partially offset higher effective tax rate supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results roche group financial review roche finance report financial position change change mchf mchf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt pensions income taxes nonoperating assets net total net assets compared start swiss franc strengthened major currencies yearend importantly us dollar japanese yen following intervention swiss national bank starting second half swiss franc stable euro pharmaceuticals division net working capital increased constant exchange rates inventories increased mainly due inventory building support recent upcoming product launches ensure supply increased sales demand meet business expansion emerging markets receivables increased impacts continued sales growth us emerging markets partly offset strong collection outstanding receivables notably southern europe payables higher previous year due increased accrued liabilities sales related chargebacks employee incentives accrued royalties longterm net operating assets decreased mainly due impact global restructuring plans lower intangible assets diagnostics net working capital decreased main driver decrease receivables strong collections factoring initiatives southern european countries offset higher inventory levels due product launches higher safety stocks due increasing market demand china decrease payables longterm net operating assets decreased intangible assets decreased additional provisions restructuring costs created decrease net debt position mainly due free cash flow billion swiss francs net pension liabilities increased billion swiss francs due continuing low interest rates increasing discounted defined benefit obligation net tax assets increased mainly due deferred tax effect increase net pension liabilities nonoperating net assets decreased due decrease interest payables free cash flow change change mchf mchf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid dividends paid free cash flow roche finance report roche group financial reviewthe groups operating free cash flow billion swiss francs increase core operating profit constant exchange rates feeding increase operating free cash flow cash generation pharmaceuticals division increased billion swiss francs strong operating results partially offset increases net working capital increased inventory holdings recently launched products additional capital expenditure property plant equipment diagnostics operating free cash flow increased due improved collection trade receivables factoring initiatives southern european countries free cash flow shows increase billion swiss francs billion swiss francs primarily due billion swiss francs increase operating free cash flow partially offset higher tax payments increase annual dividend pharmaceuticals division operating results pharmaceuticals division operating results change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps roche group financial review roche finance report sales overview pharmaceuticals division sales therapeutic area change sales sales therapeutic area mchf mchf cer oncology virology inflammationautoimmunetransplantation metabolismbone ophthalmology respiratory diseases cardiovascular diseases renal anemia central nervous system infectious diseases therapeutic areas total sales pharmaceuticals division sales increased constant exchange rates mainly due continuing strength oncology portfolio grew division benefited strong growth us china brazil growth key products offset negative impacts pricing pressures well expected decreases sales medicines due loss patent exclusivity competition sales growth primarily driven six products herceptin mabtherarituxan avastin actemraroactemra zelboraf pegasys products represent portfolio together generated billion swiss francs additional sales growth partly offset lower sales bonvivaboniva neorecormonepogin lucentis cellcept tamiflu sales increased mainly due strong influenza season us oncology continued account majority divisions sales continued growth herceptin mabthera rituxan return growth avastin recently launched zelboraf also significant growth contributor virology sales grew benefiting continued growth pegasys higher tamiflu sales us japan sales inflammationautoimmunetransplantation increased due continuing strong uptake actemraroactemra growth mabtherarituxan rheumatoid arthritis compensating negative impact continued generic erosion cellcept roche finance report roche group financial reviewproduct sales pharmaceuticals division sales change sales sales mchf mchf cer oncology herceptin avastin mabtherarituxan xeloda tarceva neutrogin zelboraf neorecormonepogin others total oncology virology pegasys valcytecymevene tamiflu others total virology inflammationautoimmunetransplantation mabtherarituxan cellcept actemraroactemra others total inflammationautoimmune transplantation metabolismbone bonvivaboniva nutropin evista xenical others total metabolismbone ophthalmology lucentis total ophthalmology respiratory diseases xolair pulmozyme total respiratory diseases roche group financial review roche finance report pharmaceuticals division sales continued change sales sales mchf mchf cer cardiovascular diseases activasetnkase others total cardiovascular diseases renal anemia neorecormonepogin mircera total renal anemia central nervous system madopar others total central nervous system infectious diseases rocephin others total infectious diseases therapeutic areas total sales total mabtherarituxan sales million swiss francs million swiss francs split oncology inflammationautoimmune transplantation franchises total neorecormonepogin sales million swiss francs million swiss francs split renal anemia oncology franchises mabtherarituxan change sales sales mchf mchf cer united states western europe japan international total sales mabtherarituxan nonhodgkins lymphoma nhl chronic lymphocytic leukemia cll rheumatoid arthritis ra sales growth oncology segment driven strong uptake firstline maintenance treatment follicular lymphoma type nhl well firstline relapsedrefractory cll us western europe sales us billion swiss francs increase sales western europe rose sales growth international region including key emerging markets russia china also mainly due uptake nhl indications increased treatment share sales grew despite mandatory price cuts markets sales ra franchise billion swiss francs increase constant currencies continued positive impact increased use patients inadequate response treatment tumour necrosis factor inhibitors roche finance report roche group financial reviewherceptin change sales sales mchf mchf cer united states western europe japan international total sales herceptin herpositive breast cancer herpositive metastatic advanced stomach cancer sales grew regions particularly international region sales grew billion swiss francs demand especially strong cemai central eastern europe middle east africa central asia indian subcontinent latin america regions us sales billion swiss francs increase largely due continued uptake stomach cancer increased availability patients resulting closure large trials positive breast cancer positive impact ongoing efforts improve quality testing believed contributed performance well testing also key growth driver western europe herceptin groups leading product sales billion swiss francs increase global growth also due programmes help improve access emerging markets japanese sales driven continued uptake stomach cancer indication avastin change sales sales mchf mchf cer united states western europe japan international total sales avastin advanced colorectal breast lung kidney ovarian cancer relapsed glioblastoma type brain tumour global sales grew mainly due increased use established indications colorectal lung breast cancer well successful launch newly diagnosed advanced ovarian cancer western europe avastin received two new eu approvals fourth quarter treatment recurrent ovarian cancer combination standard chemotherapy colorectal cancer treatment continuing firstline avastin beyond progression combination secondline chemotherapy overall avastin sales united states billion swiss francs international region growth led cemai latin america asiapacific sub regions growth japan due use breast cancer colorectal cancer lung cancer growth western europe due use ovarian cancer pegasys change sales sales mchf mchf cer united states western europe japan international total sales pegasys hepatitis b c sales increased billion swiss francs mainly due continued demand pegasys triplecombination therapy directacting hepatitis c antivirals ribavirin us sales grew western europe although sales growth slowed second half year following initial surge leading pegylated interferon pegasys established key component triplecombination treatment regimen expanding market share pegasys prefilled pen proclick us launched us key eu markets making administration medicine convenient roche group financial review roche finance report xeloda change sales sales mchf mchf cer united states western europe japan international total sales xeloda colorectal stomach breast cancer sales increased billion swiss francs growth driven primarily strong demand us china japan increased us sales partly due shortages certain alternative cancer medicines sales western europe impacted governmentmandated price cuts key markets lucentis change sales sales mchf mchf cer united states total sales lucentis wet agerelated macular degeneration wamd macular edema following central retinal vein occlusion crvo diabetic macular edema dme sales declined billion swiss francs due entry competitor drug treat wamd crvo recent launch lucentis treat dme track uptake partly offsetting decline wamd crvo roche also filed supplemental biologics license application sbla mg pro nata prn dosing wamd approved allow promotion lessthanmonthly dosing tarceva change sales sales mchf mchf cer united states western europe japan international total sales tarceva advanced nonsmall cell lung nsclc pancreatic cancer sales rose growth us brazil china japan offsetting decline western europe attributed shorter treatment durations slight decrease patient share secondline nsclc western european sales stabilised fourth quarter regulatory filings submitted approval tarceva firstline epidermal growth factor receptor egfr mutationpositive nsclc us china us submission granted priority review fda decision expected second quarter roche finance report roche group financial reviewcellcept change sales sales mchf mchf cer united states western europe japan international total sales cellcept prevention solid organ transplant rejection sales declined due continued generic erosion us western europe following patent expiry respectively sales many countries international region also negatively affected price pressure increased use generics sales grew china continued growth japan reflects position cellcept standard care approved indications actemraroactemra change sales sales mchf mchf cer united states western europe japan international total sales actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis sales continued grow strongly approved indications regions except japan volume growth offset government price cuts sales increased particularly us western europe actemraroactemra continues gain market share marketing reimbursement approvals additional countries continue expand patient access actemraroactemra physicians increasingly see actemraroactemra preferred drug monotherapy rheumatoid arthritis following positive results adacta trial showed superiority adalimumab setting neorecormonepogin change sales sales mchf mchf cer united states western europe japan international total sales neorecormonepogin anemiarenal anemia highly competitive market groups overall market share anemia franchise including mircera slightly year combined sales roches neorecormon chugais epogin epoetin beta declined western europe international regions sales lower due increasing biosimilar competition market decline cancerrelated anemia segment competitive pressure lower reimbursement price resulted reduced sales epogin japan sustained decline sales neorecormon epogin partly offset growth sales longeracting erythropoiesisstimulating agent mircera rose million swiss francs much growth due increasing number patients switching starting treatment mircera place neorecormonepogin strongest contributions higher mircera sales came japan product launched july roche group financial review roche finance report bonvivaboniva change sales sales mchf mchf cer united states western europe japan international total sales bonvivaboniva osteoporosis significant decrease us reflects falling market demand entry generics market sales western europe lower due continued impact generics market together pricing reimbursement issues growth asiapacific sub region led south korea however offset lower sales rest international region product used less competitor clinical studies tamiflu change sales sales mchf mchf cer united states western europe japan international total sales tamiflu influenza b sales increased mainly due us sales seasonal use last quarter year following strong widespread influenza season sales also higher japan partly offset lower annual sales pandemic stockpiling primarily related replacement expiring pandemic stockpiles zelboraf change sales sales mchf mchf cer united states western europe japan international total sales zelboraf braf vemutationpositive metastatic melanoma us food drug administration fda approved zelboraf august fda simultaneously approved roche diagnostics cobas braf v mutation test companion diagnostic used identify patients treatment zelboraf appropriate zelboraf approved countries sales driven continued uptake us reflecting high unmet medical need metastatic melanoma also strong uptake western europe following approval start roche finance report roche group financial reviewperjeta change sales sales mchf mchf cer united states western europe japan international total sales perjeta firstline herpositive metastatic breast cancer perjeta used treatment combinations alongside herceptin chemotherapy gained approval us switzerland mexico adoption perjeta us line expectations majority physicians treating type breast cancer prescribed perjeta pharmaceuticals division sales region change sales sales region mchf mchf cer united states western europe japan international c emai l atin america siapacific ther regions total sales central eastern europe middle east africa central asia indian subcontinent united states sales grew us dollar terms leading products oncology medicines mabtherarituxan avastin herceptin sales billion swiss francs billion swiss francs billion swiss francs respectively pegasys activasetnkase actemraroactemra zelboraf xeloda also boosted growth compensated expected declines bonvivaboniva lucentis cellcept sales tamiflu increased positive impact sales growth approximately percentage point western europe sales decreased constant currencies mainly due generic competition bonvivaboniva cellcept well price pressure government austerity measures budget constraints higher demand oncology products avastin mabtherarituxan herceptin accounted total sales billion swiss francs launch zelboraf also successful uptake actemraroactemra offset price pressures sales mircera neorecormon highly competitive renal anemia market also lower japan sales grew japanese yen terms achieved spite government price cuts negative impact sales approximately percentage points major growth drivers mircera avastin mabtherarituxan sales rose tamiflu sales sales epogin fell mainly due patient treatment switching mircera roche group financial review roche finance report international sales rose driven strong growth latin america asiapacific cemai growth latin america mainly due oncology products particular herceptin avastin mabtherarituxan sales growth particularly strong brazil argentina higher demand mabtherarituxan herceptin xeloda lifted sales asiapacific china remains main driver region overall sales growth sales growth cemai mainly due increased herceptin mabtherarituxan avastin sales driven part tender sales algeria russia sales mexico decreased due biosimilar competition mabtherarituxan total sales e key emerging markets grew pharmaceuticals division sales e leading emerging markets change cer sales sales country mchf mchf total brazil china india mexico russia south korea turkey total sales operating results pharmaceuticals division royalties operating income change mchf mchf cer royalty income income outlicensing agreements income disposal products total ifrs core basis constant currency increase due higher income royalties product disposals increase royalty income due higher lucentis royalties new royalty income eylea soliris sales significant part disposal income came disposal rocaltrol ampoules japan rights ostac vesanoid rohypnol certain markets increases partly offset lower income outlicensing agreements pharmaceuticals division cost sales change mchf mchf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets east japan earthquake total ifrs basis roche finance report roche group financial reviewcore costs decreased constant exchange rates due lower manufacturing costs royalty expenses percentage sales cost sales declined decrease manufacturing cost goods sold period costs mainly due productivity improvements product mix effects royalty expenses lower driven decline royalty expenses related sales bonvivaboniva cellcept back royalty expenses related rituxan arbitration expenses collaboration profitsharing agreements increased mainly driven higher copromotion expenses due higher sales mabtherarituxan tarceva xolair us global restructuring costs relate mostly writeoffs property plant equipment manufacturing costs related production network rationalisation dalcetrapib trial termination pharmaceuticals division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plans east japan earthquake total ifrs basis core costs increased constant exchange rates percentage sales costs fell sales marketing efforts focussed driving growth emerging markets oncology portfolio including extension avastin ovarian cancer indication new pegasys triplecombination therapy product launches zelboraf perjeta erivedge increase also partly due initiatives assisting patient access healthcare significantly lower costs incurred bad debt expenses compared global restructuring costs primarily related sales force restructuring initiatives pharmaceuticals division research development change mchf mchf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased constant exchange rates research development costs percentage sales lower compared increased investments central nervous system mostly due rampup studies bitopertin ocrelizumab ms increasing number programmes alzheimers disease partially offset lower life cycle investments inflammation oncology due decision discontinue inflammation research nutley discontinuation avastin adjuvant breast cancer studies addition pharmaceuticals division spent million swiss francs inlicensing pipeline compounds technologies capitalised intangible assets total division spent billion swiss francs internal purchased research development inlicensing alliance deals impairments intangible assets include million swiss francs decision stop development activities dalcetrapib million swiss francs returning global rights monoclonal antibody rg antiplgf mab alliance partners also million swiss francs latest clinical data assessment project acquired part marcadia acquisition addition million swiss francs impairment charges arose result portfolio prioritisation decisions following recent clinical data global restructuring costs include million swiss francs employeerelated costs million swiss francs property plant equipment impairments related closure nutley site million swiss francs following dalcetrapib trial termination consists provisions remaining trial costs writeoffs inventories restructuring costs million swiss francs mainly relate site closure costs resulting operational excellence programme roche group financial review roche finance report pharmaceuticals division general administration change mchf mchf cer administration restructuring expenses gains losses disposal property plant equipment business taxes general items general administration core basis global restructuring plans alliances business combinations legal environmental settlements east japan earthquake total ifrs basis core costs decreased constant exchange rates general administration expenses percentage sales decreased percentage points administration costs decreased due strict cost containment organisational shifts corporate functions business taxes increased mainly driven favourable tax credits global restructuring costs relate site closure costs nutley mainly impairments property plant equipment divisions global informatics restructuring programme release provision contingent consideration marcadia acquisition resulted net income alliance business combination costs roche pharmaceuticals chugai subdivisional operating results pharmaceuticals subdivisional operating results millions chf roche pharmaceuticals pharmaceuticals chugai division sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales pharmaceuticals division total core operating profit operating profit include elimination million swiss francs million swiss francs unrealised intercompany profits roche pharmaceuticals chugai sales increased subdivisions constant currencies sales core operating profit roche pharmaceuticals increased significantly sales gross profit growing operating expenses sales chugai also grew well chugai core operating profit increased despite lower gross margin due product mix effects growth core operating margin due strict cost containment operating expenses roche finance report roche group financial reviewfinancial position pharmaceuticals division net operating assets movement movement change change transactions cta mchf mchf chf cer mchf mchf receivables inventories payables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given consolidated financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start swiss franc strengthened major currencies yearend importantly us dollar japanese yen following intervention swiss national bank starting second half swiss franc stable euro net working capital increase constant exchange rates mainly due increase inventories balance sheet value inventories increased mainly due inventory building support recent launches continuing approvals new products zelboraf perjeta erivedge preparation upcoming launches tdm mabthera subcutaneous formulation higher inventory levels also driven need ensure supply increased sales demand business expansion emerging markets receivables increased sales growth us particular timing strong tamiflu sales towards year end continued growth business china latin america cemai addition royalty receivables increased due higher lucentis product royalties effects partly offset strong collections outstanding receivables southern european countries payables increased mainly due increased accrued liabilities sales related chargebacks employee incentives accrued royalties longterm net operating assets decreased constant exchange rates mainly due impact global restructuring programmes impairments intangible assets significant majority recorded first half impairments property plant equipment made respect nutley site closure provisions made employeerelated costs nutley site closure global informatics reorganisation intangibles decreased mainly due impairments respect dalcetrapib portfolio prioritisation decision regarding monoclonal antibody rg antiplgf mab impairment project acquired part marcadia acquisition impairment charges related portfolio prioritisation clinical data roche group financial review roche finance report free cash flow pharmaceuticals division operating free cash flow change mchf mchf cer operating profit depreciation amortisation impairment p rovisions equity compensation plans ther operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital r eceivables nventories p ayables total increase decrease net working capital investments property plant equipment investments intangible assets total investments operating free cash flow sales detailed breakdown provided pharmaceuticals divisions operating free cash flow increased billion swiss francs increased cash generation underlying business partly offset increases net working capital higher investments property plant equipment investments included continuing site development plans switzerland china construction new production research development facilities chugai enhancement expansion various production distribution facilities us switzerland including advanced technology quality control laboratories receivables increased lower level cash invested inventories increased due launch prelaunch preparations new products ensuring supply continued sales growth us key growth markets asiapacific especially china latin america increase cash outflow equity compensation plans increase roche share price led increasing levels exercising employee stock options roche finance report roche group financial reviewdiagnostics division operating results diagnostics division operating results change change mchf mchf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results core eps sales diagnostics division sales continued increase ahead vitro diagnostics ivd global market growth constant exchange rates professional diagnostics sales growth main growth contributor led immunodiagnostics business tissue diagnostics sales grew driven advanced staining business business areas grew substantially ahead respective markets diabetes care sales decreased mainly due reimbursement changes europe difficult market conditions sales molecular diagnostics increased led blood screening business hcv monitoring applied science sales decreased due increasing competition sequencing slowdown public research funding diagnostics division sales business area change sales sales business area mchf mchf cer professional diagnostics diabetes care molecular diagnostics applied science tissue diagnostics total sales roche group financial review roche finance report professional diagnostics change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales professional diagnostics sales grew double rate global market business area strengthened leading position professional diagnostics market includes ivd products clinical laboratories near patient testing primary growth driver immunoassay business roche diagnostics enjoys competitive advantage menu different tests broadest industry instrument series clinical chemistry solutions laboratories second largest part business saw continued demand instrument placements areas increased due strong demand emerging markets well increased supply partner hitachi high technology effects east japan earthquake point care business growth driven coagulation monitoring devices sales growth market regional view growth mainly came emerging markets led asiapacific region particularly china latin america region professional diagnostics also grew ahead market emea europe middle east africa north america particularly increased market penetration north america supported number key launches business strengthened menu tests launches four immunoassays various markets including vitamin us vitamin test seen strong market uptake worldwide million tests months since first launched eu professional diagnostics also introduced three systems near patient testing hospital physicians office cobas b blood gas accuchek inform ii blood glucose launched us cobas b blood lipidglucose launched eu new systems cobas p new preanalytics system automating preparatory steps laboratory also launched diabetes care change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales diabetes care sales declined due reimbursement cuts blood glucose monitoring supplies major european markets including germany france poland intensified pressure prices also increasing competition lowcost providers particularly us roche diabetes care launched new accuchek portfolio overall sales declined north america rest world growth driven latin america blood glucose monitoring segment declined year sales insulin delivery systems mainly due increased market uptake flexlink infusion system business introduced two products us showed promising market uptake blood glucose monitoring system accuchek nano smartview april meterpump combination accuchek combo system october diabetes care also continued launch nextgeneration accuchek mobile system eu japan available countries growing roche finance report roche group financial reviewin july diabetes care business unit initiated restructuring secure longterm profitability measures taken research development marketing distribution manufacturing activities business also reallocated rd investments continuous glucose monitoring insulin pumps expected best market potential differentiated products molecular diagnostics change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales molecular diagnostics roche molecular diagnostics retained leadership position global molecular diagnostics market holding one third global market sales growth driven blood screening business hpv cervical cancer screening microbiology businesses virology testing led demand hcv monitoring regionally growth driven north america primarily due hcv monitoring hpv testing emea growth blood screening particularly middle east partly offset lower virology sales due price pressure rest world asiapacific particularly china performed well cobas hpv test cervical cancer screening continued positive uptake eu us new contracts signed us business area also expanded instrument portfolio us preanalytical system launched three new nextgeneration tests chlamydiagonorrhoea cytomegalovirus hiv five new internal two external programmes started development companion diagnostics adding close ongoing collaborations applied science change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales applied science sales declined primarily affected subdued public research funding increasing competition gene sequencing main sales decline genomics sales sequencing microarrays lower partly offsetting growth applied sciences two market leading businesses qpcrnap instruments reagents detection quantification purification nucleic acids custom biotech raw materials reagents analytic systems healthcare industry increased respectively rest world increases qpcrnap custom biotech led growth driven latin america june onwards restructuring initiative applied science consolidating product segments focus greatest market potential consequence streamlined cellular analysis portfolio exited nimblegen microarray business keeping nimblegens sequence capture product line closed site reykjavik iceland roche group financial review roche finance report roche applied science continued invest sequencing focus area fourth quarter launched new software gs flx sequencing system enhanced longread performance introduced sequence capture products started collaboration pss automated emulsion pcr instrument improve sequencing workflow business also expanded custom biotech qpcr portfolio new bioprocess analyser cedex bio ht biopharmaceutical manufacturing lightcycler qpcr instrument lightcycler saw positive uptake close instruments sold within two months tissue diagnostics change sales sales mchf mchf cer europe middle east africa emea north america rest world total sales tissue diagnostics sales grew substantially ahead market expanding business market leadership position tissuebased cancer diagnostics regions north america sales driven instrument placements reagent growth new instrument launches partially offset recent changes reimbursement codes college american pathologists guidelines reduce use negative reagent controls roche tissue diagnostics sales growth regions reflects increasing market penetration rising demand automated tissue diagnostics solutions particularly emerging markets advanced staining systems reagents pathology labs detect proteins genes tissue samples remained primary growth driver sales increase due increasing reagent sales well placements benchmark series instruments supported companion diagnostics business doubled revenues research diagnostic biomarkers product development work partners pharmaceuticals industry business initiated ten new companion diagnostic projects partners roche tissue diagnostics launched benchmark special stains platform ventana iscan ht scanner positive market uptake together accounting placements business also expanded advanced staining menu new immunohistochemistry ihc reagents including tests lung pancreatic prostate cancer one alk anaplastic lymphoma kinase ihc key companion diagnostic launched october eu parallel pfizers crizotinib select patients likely benefit lung cancer drug diagnostics division sales region change sales sales region mchf mchf cer europe middle east africa emea north america asiapacific latin america japan total sales divisional sales growth primarily driven asiapacific latin america regions professional diagnostics continued main growth driver substantial increases diabetes care latin america north america saw growth clinical laboratory business professional tissue molecular diagnostics creation growth momentum launch major products us japan sales grew three times rate market driven professional diagnostics emea region austerity measures price pressure felt major european markets particularly impacted diabetes care business professional tissue diagnostics continued grow sales gain market share roche finance report roche group financial reviewdiagnostics division sales e leading emerging markets change sales sales country mchf mchf cer brazil china india mexico russia south korea turkey total sales sales growth e emerging markets led china substantial contributions brazil india russia growth china driven governments continued efforts improve healthcare system along roche diagnostics investments strengthen market presence expand customer base beyond large cities hospitals growth brazil came continued success major public private tenders laboratory solutions india major public contract diabetes care growth laboratory business operating results diagnostics division royalties operating income change mchf mchf cer royalty income income outlicensing agreements income disposal products total ifrs core basis royalty operating income increased constant exchange rates mainly result back royalty payments well service royalty growth molecular diagnostics receipt royalty payment diabetes care income outlicensing agreements decreased various upfront onetime payments received diagnostics division cost sales change mchf mchf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis roche group financial review roche finance report cost sales increased constant exchange rates core basis primarily due increase manufacturing cost goods sold period costs previous cost reduction initiatives continued positive impact effect offset increase period costs driven higher depreciation placement installation costs new instruments manufacturing cost goods sold increased due changes product mix increase overall installed instrument base instrument placements clinical chemistry immunology businesses driven strong customer demand partly due installation instruments sourced hitachi high technologies subject supply disruptions following east japan earthquake march increase royalty expenses due higher sales products inlicensed intellectual property overall cost growth core basis sales growth resulting higher cost sales ratio global restructuring costs incurred mainly due costs related closure graz burgdorf sites reorganisations applied science diabetes care businesses amortisation product intangibles decreased intangible assets fully amortised diagnostics division marketing distribution change mchf mchf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis increase constant exchange rates core basis mainly reflects higher costs professional molecular diagnostics driven sales force increases china factoring costs related reduction outstanding trade receivables southern europe whole division core basis marketing distribution costs percentage sales remained global restructuring costs incurred mainly due reorganisations applied science business diagnostics division research development change mchf mchf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased constant exchange rates driven development new immunoassays tests professional diagnostics cobas platform molecular diagnostics instruments tissue diagnostics increases partially offset cost savings applied science diabetes care percentage sales research development costs stable global restructuring costs mainly due costs related operational excellence programme reorganisation diabetes care business roche finance report roche group financial reviewdiagnostics division general administration change mchf mchf cer administration restructuring expenses gains losses disposal property plant equipment general items general administration core basis global restructuring plans impairment intangible assets alliances business combinations legal environmental settlements total ifrs basis costs increased constant exchange rates core basis cost increase administration mainly driven investments various efficiency initiatives mostly consisting costs formation new sales distribution entities costs general items increased compared base effect due income release provision royalties percentage sales costs increased percentage points global restructuring costs mainly due employeerelated costs arising graz transfer smaller extent applied science business area addition goodwill impairment charges million swiss francs incurred full writeoff goodwill nimblegen acquisition resulting decision exit microarrays business part reorganisation applied science business area financial position diagnostics division net operating assets movement movement change change transactions cta mchf mchf chf cer mchf mchf receivables inventories payables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow include cash movements full consolidated balance sheet given consolidated financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start swiss franc strengthened major currencies yearend importantly us dollar japanese yen following intervention swiss national bank starting second half swiss franc stable euro roche group financial review roche finance report net working capital net working capital decreased constant exchange rates increases inventories decreases payables offset reduction receivables inventory increases due launch growth key products professional diagnostics tissue diagnostics higher safety stock levels asia pacific mainly south korea china vietnam due increasing market demand establishment middleeast hub main factors decreases receivables strong collections factoring initiatives southern european countries regions except north america show reduction receivables ratios compared payables decreased compared end due lower accruals lower trade payables longterm net operating assets decrease constant exchange rates due decrease intangible assets due nimblegen goodwill impairment increases provisions mainly due global restructuring plans property plant equipment increased additions especially due high instrument placements china partially offset depreciation free cash flow diagnostics division operating free cash flow change mchf mchf cer operating profit depreciation amortisation impairment p rovisions equity compensation plans ther operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital r eceivables nventories p ayables total increase decrease net working capital investments property plant equipment investments intangible assets total investments operating free cash flow sales detailed breakdown provided operating free cash flow diagnostics division increased constant exchange rates despite decline operating profit primarily due lower increase net working capital compared strong collection trade receivables cash received factoring initiatives resulted decrease receivables higher inventory levels resulted launch growth key products professional diagnostics tissue diagnostics higher safety stock levels asia pacific mainly south korea china vietnam due increasing market demand establishment middleeast hub payables decreased due lower accruals lower trade payables capital expenditure property plant equipment increased mainly driven investments china total operating free cash flow margin increased percentage points roche finance report roche group financial reviewcorporate operating results corporate operating results summary change mchf mchf cer administration gains losses divestment subsidiaries general items general administration costs core basis global restructuring plans alliances business combinations legal environmental settlements total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow see pages definition core results core eps general administration costs increased constant exchange rates result shift certain functions pharmaceuticals diagnostics divisions corporate increased human resources informatics costs various initiatives total costs ifrs basis grew due increased environmental provisions million swiss francs initial estimate costs additional remediation activities may needed nutley site us prior sold environmental costs estimated additional remediation costs landfill site near grenzach germany previously used manufacturing operations closed years ago details matters given notes consolidated financial statements corporate operating free cash flow showed increase net outflow driven higher administration expenses described roche group financial review roche finance report foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer swiss francs change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit exchange rates swiss franc december average december average usd eur jpy average swiss franc weaker compared average rates many currencies including us dollar japanese yen stronger others notably euro brazilian real overall impact positive income statement cash flows expressed swiss francs compared results constant exchange rates sales developments resulted positive impact percentage points equivalent billion swiss francs translated swiss francs currency translation exposure operating profit mitigated group majority cost base located outside switzerland core operating profit increased swiss francs compared increase constant exchange rates positive impact percentage points equivalent billion swiss francs sensitivity group sales core operating profit movement average foreign currency exchange rates swiss franc shown table currency sensitivities impact rise average exchange rate sales core operating profit versus swiss franc mchf mchf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro costs sales marketing also administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany obviously large majority chugais costs denominated japanese yen roche finance report roche group financial reviewtreasury taxation results treasury taxation results change change mchf mchf chf cer ifrs results operating profit associates financial income financing costs profit taxes income taxes net income attributable r oche shareholders n oncontrolling interests core results operating profit associates financial income financing costs profit taxes income taxes net income attributable r oche shareholders n oncontrolling interests financial position treasury taxation net debt pensions income taxes financial longterm assets derivatives net collateral net interest payable nonoperating assets net total net assets liabilities free cash flow treasury taxation treasury activities taxes paid dividends paid total see pages definition core results core eps financial income financial income million swiss francs decrease compared interest income income debt securities million swiss francs decrease due low prevailing interest rates net foreign exchange result reflects hedging costs loss million swiss francs compared gain million swiss francs net income equity securities million swiss francs expected returns pension plan assets million swiss francs broadly line full analysis financial income given note consolidated financial statements roche group financial review roche finance report financing costs financing costs million swiss francs decrease compared main driver decrease interest expenses reflects continued repayment debt incurred finance genentech transaction financing costs also include million swiss francs loss combined repurchase million euros notes due march million euros notes due march exercise groups option call early redemption billion us dollars notes due march comparative period contained million swiss francs loss early redemption debt interest cost pension plans remained largely stable million swiss francs full analysis financing costs given note consolidated financial statements income taxes groups effective core tax rate increased percentage points main reason increase effective tax rate higher percentage core profit contribution us relatively higher local tax rate average group rate tax benefit million swiss francs recorded noncore items described compared tax benefit million swiss francs increase primarily due higher tax benefit resulting global restructuring plans including intangible asset impairments well legal environmental costs compared partially offset tax effects costs resulting east japan earthquake full details groups income tax positions given note consolidated financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate mchf mchf mchf mchf groups effective tax rate core basis global restructuring plans intangible assets groups effective tax rate ifrs basis financial position decrease net debt position due increased operating free cash flow offset higher tax payments increase annual dividend fully described net debt section increase net pension liabilities reflects falling interest rates leading discounted defined benefit obligation higher net tax assets increased mainly due deferred tax effect increased net pension liabilities net derivative position increased net asset billion swiss francs mainly due higher valuations crosscurrency swaps following stronger euro compared us dollar interest payable relates mostly bonds notes coupon payment dates march september decline mostly due ongoing debt redemptions december group held financial longterm assets market value billion swiss francs consist mostly holdings biotechnology companies acquired context licensing transactions scientific collaborations free cash flow cash outflow treasury activities remained stable billion swiss francs total taxes paid billion swiss francs increase constant exchange rates due higher tax payments united states chugai settlement certain outstanding tax positions total dividends paid billion swiss francs increase billion swiss francs compared reflecting increase roche group dividend roche finance report roche group financial reviewcash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow millions chf pharmaceuticals diagnostics corporate group operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid dividends paid free cash flow operating free cash flow increased constant exchange rates billion swiss francs mainly due continued growth underlying operating business showed increase core operating profit pharmaceuticals strong operating results partially offset increases net working capital higher investments property plant equipment diagnostics operating free cash flow increased significantly due improved collection trade receivables factoring initiatives southern european countries cash outflow treasury activities remained stable billion swiss francs total taxes paid billion swiss francs increase due higher tax payments united states chugai settlement certain outstanding tax positions total dividends paid also higher due increase annual roche group dividend free cash flow billion swiss francs billion swiss francs higher increase due growth operating free cash flow partly offset higher tax dividend payments roche group financial review roche finance report net debt millions chf december cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow transactions equity instruments business combinations net divestments subsidiaries hedging collateral arrangements currency translation fair value movements change net debt period december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period net debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen pound sterling total us dollardenominated debt includes bonds notes denominated euros swiss francs pounds sterling swapped us dollars therefore financial statements economic characteristics equivalent us dollardenominated bonds notes net debt position group december billion swiss francs decrease billion swiss francs december decrease net debt mainly due free cash flow billion swiss francs described issuing debt finance genentech transaction group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued currencies us dollar total exposure hedged issuance bonds notes approximately billion swiss francs collateral agreements entered derivative counterparties mitigate counterparty risk cash collateral billion swiss francs delivered roche increased cash collateral balance billion swiss francs start year billion swiss francs december collateral balance relation hedges nonus dollardenominated bonds notes mainly sensitive foreign exchange rate us dollar euro also pound sterling currently collateral balance moves approximately million us dollars foreign exchange rates move simultaneously collateral volatility decrease less million us dollars movement foreign exchange rates mid significant portion nonus dollardenominated bonds notes repaid time roche finance report roche group financial reviewthe redemption repurchase bonds notes also issuance new bonds notes described note consolidated financial statements direct impact liquid funds however material impact net debt position full details groups marketable securities cash debt positions given notes consolidated financial statements pensions postemployment benefits postemployment benefit plans classified defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans million swiss francs million swiss francs plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising funding asset management groups various defined benefit plans overseen corporate level plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources funding status balance sheet position mchf mchf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status unrecognised past service costs limit asset recognition reimbursement rights net recognised asset liability funding status overall funding status ifrs basis groups defined benefit plans decreased compared start year decrease came mainly increase defined benefit obligation arising fall discount rates comparison end plan assets increased company contributions increasing million swiss francs compared million swiss francs group continues closely monitor funded status major pension funds addition cash injections group initiated plan changes several local pension plans example major pension funds removing early retirement incentives group continues introduce flexible retirement models better accommodate diverse needs ageing workforce roche group financial review roche finance report expenses recorded income statement total pension expenses relating groups defined benefit plans million swiss francs compared million swiss francs decrease primarily due higher curtailment gains million swiss francs related nutley restructuring compared million swiss francs curtailment gains based revised actuarial assumptions end total pension expenses expected approximately million swiss francs higher increase mainly driven application ias revised increase net interest cost pensions approximately million swiss francs also increase approximately million swiss francs current service cost driven fall discount rates estimates pension expenses include curtailment past service effects might arise year full details groups pensions postemployment benefits given note consolidated financial statements roche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group healthcare companies total shareholder return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange rates roche ranked number yearend return roche shares roche nonvoting equity securities combined performance share nonvoting equity security compared weighted average return peer group swiss franc terms constant exchange rates share prices healthcare outperformed many sectors despite continuing pressure healthcare prices sovereign debt issues europe usa good roche news flow rewarded relatively strong share price performance peer group abbott laboratories amgen astellas astrazeneca bayer becton dickinson bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer roche sanofiaventis takeda total shareholder return development dec march june sept dec roche share roche nonvoting equity security peer set index roche finance report roche group financial reviewproposed dividend board directors proposing increase dividend swiss francs per share nonvoting equity security swiss francs approval annual general meeting th consecutive increase dividend dividend proposal approved shareholders dividend payments total shares nonvoting equity securities amount billion swiss francs billion swiss francs resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security information roche securities given pages finance report information per share nonvoting equity security change chf chf chf basic eps diluted eps core eps equity attributable roche shareholders per share dividend per share details please refer notes consolidated financial statements pages finance report payout ratio calculated dividend per share divided core earnings per share roche group financial review roche finance report debt finance genentech transaction group issued bonds notes equivalent billion swiss francs february march debt raised early already repaid december includes redemption billion swiss francdenominated notes due date march billion euros notes originally due march repurchased march following tender offer billion euros notes originally due march repurchased november following tender offer billion euros notes originally due march repurchased november following tender offer furthermore december group exercised option call early redemption billion us dollars notes due march notes repaid march group issued total billion swiss francs notes due also issued billion euros notes due bonds coupons issued partly refinance debt redemptions attractive market environment maturity schedule groups bonds notes outstanding december shown table includes instruments already issue prior genentech transaction bonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc total total musd meur mgbp mchf musd mchf beyond total total translated december exchange rates following groups exercise early call option december bond redeemed march one year ahead contractual maturity proceeds bonds notes billion euros swapped us dollars therefore financial statements economic characteristics equivalent us dollardenominated bonds notes proceeds bonds notes million pounds sterling swapped us dollars therefore financial statements economic characteristics equivalent us dollardenominated bonds notes group plans meet debt obligations using existing liquid funds well cash generated business operations full year free cash flow billion swiss francs included cash generated operations well payment interest tax dividends shortterm financing requirements group commercial paper programme united states issue billion us dollars unsecured commercial paper notes committed credit lines billion euros available backstop lines commercial paper notes totalling billion us dollars outstanding december longerterm financing group maintains strong longterm investmentgrade credit ratings moodys aa standard poors facilitate efficient access international capital markets credit ratings roche group december shortterm longterm outlook moodys p stable standard poors aa stable described commentary net debt position group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued currencies us dollar time collateral agreements entered derivative counterparties mitigate counterparty risk roche finance report roche group financial reviewfinancial risks december group net debt position billion swiss francs december billion swiss francs financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt redemptions liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities mchf total mchf total cash cash equivalents money market instruments bonds debentures investments shares total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups billion swiss francs cash fixed income marketable securities remained strong invested aaaa range noted previously group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions december group trade receivables billion swiss francs since beginning increasing financial difficulties certain southern european countries notably spain italy portugal greece group leading supplier countries trade receivables billion swiss francs public customers countries group uses different measures improve collections countries including intense communication customers negotiations payment plans charging interest late payments legal action group also applying new commercial arrangements public hospitals greece portugal liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years despite total debt billion swiss francs december roche enjoys strong longterm investmentgrade credit ratings moodys aa standard poors time roche rated highest available shortterm ratings agencies event financing requirements ratings strong credit roche permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling billion swiss francs billion swiss francs serve backstop line commercial paper programme december debt drawn credit lines market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices var data table indicates economic loss level period one month probability exceeded actual future economic gains losses associated treasury activities may differ materially var analyses performed due inherent limitations associated predicting timing amount changes interest rates foreign currency exchanges rates equity investment prices particularly periods high market volatilities furthermore var numbers include credit risk component roche group financial review roche finance report market risk financial instruments december december mchf mchf var interest rate component var foreign exchange component var price component diversification var total interest rate var decreased reflecting ageing debt repayment debt issued debt held amortised cost interest rate var sole metric economic fair value changes impact carrying value profit loss group foreign exchange var remained stable price risk arises mainly movements prices equity securities remained largely stable december group held equity securities market value billion swiss francs includes holdings biotechnology companies acquired context licensing transactions scientific collaborations information financial risk management financial risks var methodology included note consolidated financial statements roche finance report roche group financial reviewinternational financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since group implemented various minor amendments existing standards interpretations material impact groups overall results financial position various new standards issued described note consolidated financial statements implemented latest except noted based analysis date group anticipate material impact groups overall results financial position amongst matters revised version ias employee benefits includes following changes existing standard e liminating option defer recognition actuarial gains losses defined benefit postemployment plans known corridor method group currently apply option rather uses option recognise gains losses comprehensive income option currently applied group henceforth requirement revised standard therefore change impact groups financial statements current method including expected income plan assets estimated asset return would replaced using discount rate used discount defined benefit obligation group estimates method applied consolidated financial statements net financial income would approximately million swiss francs lower published operating profit would materially affected roche group financial review roche finance report roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statementsroche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche group roche group consolidated financial statements roche finance report roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total roche finance report roche group roche group consolidated financial statementsroche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment goodwill intangible assets associates financial longterm assets longterm assets deferred income tax assets postemployment benefit assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred income tax liabilities postemployment benefit liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable accrued current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity roche group roche group consolidated financial statements roche finance report roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease working capital payments made defined benefit postemployment plans utilisation provisions disposal products operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations divestment subsidiaries interest dividends received sales marketable securities purchases marketable securities investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements equity contribution noncontrolling interests interest paid dividends paid equitysettled equity compensation plans net transactions equity instruments financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december roche finance report roche group roche group consolidated financial statementsroche group consolidated statement changes equity millions chf non share retained fair value hedging translation controlling total capital earnings reserves reserves reserves total interests equity year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans total comprehensive income dividends equity compensation plans net transactions equity instruments changes noncontrolling interests december year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans total comprehensive income dividends equity compensation plans net transactions equity instruments changes noncontrolling interests equity contribution noncontrolling interests december roche group roche group consolidated financial statements roche finance report notes roche group consolidated financial statements reference numbers indicate corresponding notes consolidated financial statements summary significant accounting policies basis preparation consolidated financial statements consolidated financial statements hereafter annual financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except disclosed accounting policies certain items including derivatives availableforsale investments shown fair value approved issue board directors january subject approval annual general meeting shareholders march preparation annual financial statements requires management make estimates assumptions affect reported amounts revenues expenses assets liabilities disclosure contingent liabilities date financial statements future estimates assumptions based managements best judgement date financial statements deviate actual circumstances original estimates assumptions modified appropriate year circumstances change consolidation policy financial statements annual financial statements roche holding ltd company registered switzerland subsidiaries group subsidiaries companies controlled directly indirectly roche holding ltd control defined power govern financial operating policies enterprise obtain benefits activities control normally evidenced roche holding ltd owns either directly indirectly voting rights currently exercisable potential voting rights companys share capital special purpose entities consolidated substance relationship special purpose entity controlled group companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control investments associates accounted using equity method companies group exercises power exercise significant influence control normally evidenced group owns voting rights currently exercisable potential voting rights company balances transactions associates result unrealised income eliminated extent groups interest associate interests joint ventures reported using linebyline proportionate consolidation method roche finance report roche group notes roche group consolidated financial statementssegment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include cec global group functions communications human resources finance including treasury taxes pension fund management legal safety environmental services subdivisional information roche pharmaceuticals chugai operating segments within pharmaceuticals division also presented transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation group companies use local currency functional currency certain group companies use currencies us dollars swiss francs euros functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs foreign entities translated swiss francs using yearend rates exchange sales costs expenses net income cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income disposal foreign entity identified cumulative currency translation differences within comprehensive income relating foreign entity recognised income part gain loss divestment revenues sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid united states similar rebates countries also deducted sales recorded accrued liabilities provisions deduction accounts receivable estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience circumstances level sales returns hence revenues reliably measured sales recognised right return expires generally upon prescription products patients revenues recorded earned services performed necessary single transactions split separately identifiable components reflect substance transaction conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole roche group notes roche group consolidated financial statements roche finance report cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research costs costs incurred purpose gaining new scientific technical knowledge understanding costs expensed incurred internal development costs costs incurred application research findings knowledge plan develop new products commercial production costs would qualify capitalisation intangible assets following criteria demonstrated technical feasibility completing development project successfully available use sale intention complete development project ability use sell results development project development project would generate economic benefits would normally evidenced existence size market results project products would result project availability adequate technical financial resources complete development project ability measure development expenditure reliably would qualify capitalisation intangible asset development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation met prior obtaining marketing approval regulatory authorities major markets internal development costs meet criteria therefore expensed incurred postmarketing studies regulatory approval phase iv costs pharmaceuticals business expensed incurred generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons safety surveillance designed detect rare longterm adverse effects much larger patient population longer time period possible earlier stages development costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured addition internal research development activities group also party inlicensing similar arrangements alliance partners group may also acquire inprocess research development assets either business combinations purchases specific assets inprocess research development resources acquired either inlicensing arrangements business combinations separate purchases capitalised intangible assets controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy reviewed impairment set impairment property plant equipment intangible assets policy subsequent internal research development costs incurred postacquisition treated way internal research development costs available use intangible assets amortised straightline basis period expected benefit reviewed impairment reporting date research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition asset roche finance report roche group notes roche group consolidated financial statementslicensing milestone upfront receipts royalty income recognised accrual basis accordance substance respective licensing agreements collectability royalty amount reasonably assured royalties recognised revenue cash received certain group companies receive upfront milestone similar payments third parties relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing obligation employee benefits wages salaries social security contributions paid annual leave sick leave bonuses nonmonetary benefits accrued year associated services rendered employees group group provides longterm employee benefits cost accrued match rendering services employees concerned liabilities longterm employee benefits discounted take account time value money material pensions postemployment benefits employees covered defined benefit defined contribution postemployment plans sponsored group companies groups contributions defined contribution plans charged appropriate income statement heading within operating results year relate accounting reporting defined benefit plans based recent actuarial valuations defined benefit obligations service costs calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth longterm expected rates return plan assets discount rates based market yields highquality corporate bonds government bonds countries deep market corporate bonds past service costs allocated average period benefits become vested current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses consist differences assumptions actual experiences effects changes actuarial assumptions recorded directly comprehensive income pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly comprehensive income equity compensation plans certain employees group participate equity compensation plans including separate plans chugai fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equity settled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity cashsettled plans liability recorded measured fair value reporting date movements fair value recorded appropriate income statement heading within operating results subsequent cash flows exercise vested awards recorded reduction liability roche group notes roche group consolidated financial statements roche finance report property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred leases group lessee leases property plant equipment group substantially risks rewards ownership classified finance leases finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt assets acquired finance leases depreciated accordance groups policy property plant equipment reasonable certainty group obtain ownership end lease term asset depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method leases substantially risks rewards ownership transferred group classified operating leases payments made operating leases charged income straightline basis period lease group lessor primarily occurs diagnostics division assets subject finance leases initially reported receivables amount equal net investment lease assets subject operating leases reported within property plant equipment lease income finance leases subsequently recognised earned income term lease based effective interest rate method lease income operating leases recognised lease term straightline basis business combinations goodwill business combinations accounted using acquisition method accounting consideration transferred business combination measured fair value date acquisition consideration includes cash paid plus fair value date exchange assets given liabilities incurred assumed equity instruments issued group fair value consideration transferred also includes contingent consideration arrangements fair value directly attributable acquisitionrelated costs expensed current period reported within general administration expenses date acquisition group recognises identifiable assets acquired liabilities assumed noncontrolling interest acquired business identifiable assets acquired liabilities assumed initially recognised fair value group acquire ownership acquired business noncontrolling interests recorded proportion fair value acquired net assets attributable noncontrolling interest roche finance report roche group notes roche group consolidated financial statementsgoodwill excess fair value consideration transferred amount noncontrolling interest acquired business acquisition date fair value previous equity interest acquired business fair value groups share identifiable net assets acquired initial accounting business combination incomplete end reporting period provisional amounts used measurement period provisional amounts retrospectively adjusted additional assets liabilities may recognised reflect new information obtained facts circumstances existed acquisition date would affected measurement amounts recognised date known measurement period exceed twelve months date acquisition goodwill amortised tested impairment least annually upon occurrence indication impairment goodwill may also arise upon investments associates surplus cost investment groups share fair value net identifiable assets goodwill recorded within investments associates changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination fair value allocated acquisition accounting intangible assets amortised useful lives straightline basis beginning point available use estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use years impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs sell value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm interest rate impairment loss arises useful life asset question reviewed necessary future depreciationamortisation charge accelerated impairment financial assets discussed financial assets policy impairment goodwill goodwill assessed possible impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units described note recoverable amount cashgenerating unit higher fair value less costs sell value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss methodology used impairment testing described note inventories inventories stated lower cost net realisable value cost finished goods work process includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses roche group notes roche group consolidated financial statements roche finance report accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded difference carrying value estimated recoverable amount objective evidence group able collect amounts due estimates based specific indicators ageing customer balances specific credit circumstances groups historical experience taking also account economic conditions expenses doubtful trade receivables recognised consolidated income statement within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience longterm accounts receivable discounted take account time value money material cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash readily convertible known amounts cash subject insignificant risk changes value maturity three months less date acquisition definition also used statement cash flows provisions provisions recognised legal constructive obligation incurred probably lead outflow resources reasonably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise taking account foreign currency effects arising translation functional currency swiss francs time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available fair value hierarchy valuation techniques incorporate observable market data market conditions factors likely affect fair value financial instrument valuation techniques typically used derivative financial instruments fair values financial assets liabilities reporting date materially different reported carrying values unless specifically mentioned notes annual financial statements information fair value hierarchy included note risk management financial assets financial assets principally investments including marketable securities classified either fairvaluethroughprofit orloss availableforsale heldtomaturity loans receivables fairvaluethroughprofitorloss financial assets either classified heldfortrading designated upon initial recognition heldfortrading financial assets acquired principally generate profit shortterm fluctuations price financial assets designated fairvaluethrough profitorloss results relevant information eliminating measurement recognition inconsistency heldtomaturity financial assets securities fixed maturity group intent ability hold maturity loans receivables financial assets created group acquired issuer primary market nonderivative financial assets fixed determinable payments quoted active market financial assets considered availableforsale roche finance report roche group notes roche group consolidated financial statementsall financial assets initially recorded fair value including transaction costs except assets fairvaluethrough profitorloss exclude transaction costs purchases sales recognised settlement date fairvalue throughprofitorloss financial assets subsequently carried fair value changes fair value recorded financial income period arise heldtomaturity financial assets subsequently carried amortised cost using effective interest rate method availableforsale financial assets subsequently carried fair value unrealised changes fair value recorded comprehensive income except interest calculated using effective interest rate method foreign exchange components availableforsale financial assets sold impaired otherwise disposed cumulative gains losses previously recognised comprehensive income included financial income current period loans receivables subsequently carried amortised cost using effective interest rate method financial assets individually assessed possible impairment reporting date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty addition availableforsale equity securities market value original cost net previous impairment considered impaired availableforsale equity securities market value original cost net previous impairment sustained sixmonth period also considered impaired decreases market price less original cost net previous impairment also less sustained sixmonth period considered objective evidence impairment movements fair value recorded comprehensive income objective evidence impairment asset sold otherwise disposed financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried comprehensive income difference original cost net previous impairment fair value impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held availableforsale reversal recognised directly comprehensive income financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred interest transferred financial assets created retained group recognised separate asset liability derivatives derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments discussed hedge accounting policy changes fair value recorded financial income period arise embedded derivatives recognised separately closely related host contract host contract carried amortised cost hedge accounting purposes hedge accounting hedging relationships may three types fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedge net investment foreign operation hedge foreign currency exposure net investment foreign operation roche group notes roche group consolidated financial statements roche finance report qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence cash flow hedges hedge effectiveness reliability measurement conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship particular derivatives reported fair value changes fair value included financial income qualifying fair value hedges hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income qualifying cash flow hedges hedging instrument recorded fair value portion change fair value effective hedge included comprehensive income remaining ineffective portion reported financial income hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial asset liability cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value asset liability date recognition qualifying cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income forecasted transaction affects net income qualifying hedges net investment foreign entity hedging instrument recorded fair value portion change fair value effective hedge included comprehensive income remaining ineffective portion recorded financial income hedging instrument derivative comprehensive income cases entity disposed cumulative changes fair value hedging instrument recorded comprehensive income reclassified income debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method group derecognises financial liability contractual obligations discharged cancelled expired taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future deferred income tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values financial statements deferred income tax assets relating carryforward unused tax losses recognised extent probable future taxable profit available unused tax losses utilised current deferred income tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred income taxes determined based currently enacted tax rates applicable tax jurisdiction group operates roche finance report roche group notes roche group consolidated financial statementsown equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments acquired primarily meet potential obligations employees may arise respect certain groups equity compensation plans management judgements made applying accounting policies application groups accounting policies may require management make judgements apart involving estimates significant effect amounts recognised annual financial statements management judgement particularly required assessing substance transactions complicated structure legal form include limited following areas revenue recognition nature groups business many sales transactions simple structure sales agreements may consist multiple components occurring different times group also party various outlicensing agreements involve upfront milestone payments may occur several years agreements may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement consolidation subsidiaries associates group periodically undertakes transactions may involve obtaining right control significantly influence operations companies transactions include acquisition part equity companies purchase certain assets assumption certain liabilities contingent liabilities companies entering alliance agreements companies also included transactions involving special purpose entities similar vehicles cases management makes assessment whether group right control significantly influence companys operations based assessment company consolidated subsidiary associated company making assessment management considers underlying economic substance transaction contractual terms business combinations group acquires control another business identifiable assets acquired liabilities assumed noncontrolling interest acquired business shall recognised separately goodwill process involves management making assessment fair value items management judgement particularly involved recognition measurement following items intellectual property may include patents licences trademarks similar rights currently marketed products also rights scientific knowledge associated projects currently research development phases contingencies legal environmental matters contingent consideration arrangements recoverability accumulated tax losses previously incurred acquired company cases management makes assessment based underlying economic substance items concerned contractual terms order fairly present items leases group party leasing arrangements lessee lessor treatment leasing transactions financial statements mainly determined whether lease considered operating lease finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments roche group notes roche group consolidated financial statements roche finance report key assumptions sources estimation uncertainty preparation annual financial statements conformity ifrs requires management make estimates assumptions affect application policies reported amounts assets liabilities income expenses related disclosures estimates underlying assumptions based historical experience various factors believed reasonable circumstances results form basis making judgements carrying values assets liabilities readily apparent sources actual results may differ estimates estimates underlying assumptions reviewed ongoing basis changes accounting estimates may necessary changes circumstances estimate based result new information experience changes recognised period estimate revised key assumptions future key sources estimation uncertainty significant risk causing material adjustment carrying value assets liabilities within next twelve months described revenue recognition may circumstances level sales returns hence revenues reliably measured cases sales recognised right return expires generally upon prescription products patients order estimate management uses publicly available information prescriptions well information provided wholesalers intermediaries sales allowances group provisions accruals expected sales returns chargebacks rebates including medicaid united states similar rebates countries december total million swiss francs estimates based analyses existing contractual legislativelymandated obligations historical trends groups experience management believes total provisions accruals items adequate based upon currently available information deductions based management estimates may subject change better information becomes available changes arise could impact provisions accruals recognised balance sheet future periods consequently level sales recognised income statement future periods allowances doubtful accounts receivable group provisions doubtful receivables december total million swiss francs see note estimates based analyses ageing customer balances specific credit circumstances historical trends groups experience taking also account economic conditions management believes total provisions accruals items adequate based upon currently available information provisions based management estimates may subject change better information becomes available changes arise could impact provisions recognised balance sheet future periods consequently marketing distribution expenses recognised income statement future periods property plant equipment intangible assets including goodwill group property plant equipment carrying value million swiss francs disclosed note goodwill carrying value million swiss francs see note intangible assets carrying value million swiss francs see note assets reviewed annually impairment described assess whether impairment exists estimates made future cash flows expected result use asset eventual disposal actual outcomes could vary significantly estimates discounted future cash flows factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment changes discount rates used could also lead impairments roche finance report roche group notes roche group consolidated financial statementspensions postemployment benefits many groups employees participate postemployment defined benefit plans calculations recognised assets liabilities plans based upon statistical actuarial calculations particular present value defined benefit obligation impacted assumptions discount rates used arrive present value future pension liabilities assumptions future increases salaries benefits furthermore groups independent actuaries use statistically based assumptions covering areas future withdrawals participants plan estimates life expectancy december present value groups defined benefit obligation million swiss francs funded plans million swiss francs unfunded plans see note actuarial assumptions used may differ materially actual results due changes market economic conditions higher lower withdrawal rates longer shorter life spans participants changes factors assessed differences could impact assets liabilities recognised balance sheet future periods legal provisions group companies party various legal matters including claims arising trade significant matters described note legal provisions december total million swiss francs management believes total provisions legal matters adequate based upon currently available information legal matters involve highly complex issues subject substantial uncertainties therefore probability loss sustained estimate amount loss difficult ascertain given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued additional claims could made might covered existing provisions insurance assurance increase scope matters future lawsuits claims proceedings investigations material changes arise could impact provisions recognised balance sheet future periods number legal matters possible make reasonable estimate expected financial effect result ultimate resolution matters cases roche discloses information respect nature facts legal matters disclosure legal matters provided disclosed contingent liabilities made would seriously prejudice position matters environmental provisions group provisions environmental remediation costs december total million swiss francs disclosed note material components environmental provisions consist costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites future remediation expenses affected number uncertainties include limited detection previously unknown contaminated sites method extent remediation percentage problematic materials attributable group remediation sites relative attributable parties financial capabilities potentially responsible parties management believes total provisions environmental matters adequate based upon currently available information however given inherent difficulties estimating liabilities area guaranteed additional costs incurred beyond amounts accrued effect resolution environmental matters results operations predicted due uncertainty concerning amount timing future expenditures changes arise could impact provisions recognised balance sheet future periods income taxes december net liability current income taxes million swiss francs net asset deferred income taxes million swiss francs disclosed note significant estimates required determine current deferred assets liabilities income taxes estimates based interpretations existing tax laws regulations management believes estimates reasonable recognised liabilities income taxrelated uncertainties adequate various internal external factors may favourable unfavourable effects income tax assets liabilities factors include limited changes tax laws regulations andor rates changing interpretations existing tax laws regulations future levels research development spending changes overall levels pretax earnings changes arise could impact assets liabilities recognised balance sheet future periods roche group notes roche group consolidated financial statements roche finance report changes accounting policies changes accounting policies arise application new revised standards interpretations applied retrospectively unless transitional requirements particular standard interpretation specify changes applied prospectively retrospective application requires results comparative period opening balances period restated new accounting policy always applied prospective application requires new accounting policy applied results current period comparative period restated comparatives reclassified extended previously reported results take account presentational changes required application new revised standards interpretations changes ifrs implemented group implemented various minor amendments existing standards interpretations material impact groups overall results financial position new revised standards following new standards issued international accounting standards board iasb implemented january ifrs consolidated financial statements ifrs joint arrangements ifrs disclosure interests entities ifrs fair value measurement ias revised employee benefits group expect adoption standards listed material impact groups overall results financial position except ias revised employee benefits revised version ias adopted january applied retrospectively amongst matters revised version ias employee benefits includes following changes existing standard eliminating option defer recognition actuarial gains losses defined benefit postemployment plans known corridor method group currently apply option rather uses option recognise gains losses directly comprehensive income option currently applied group henceforth requirement revised standard therefore change impact groups financial statements current method including expected income plan assets estimated asset return would replaced using discount rate used discount defined benefit obligation group estimates method applied annual financial statements net financial income would approximately million swiss francs lower published operating profit would materially affected roche finance report roche group notes roche group consolidated financial statements operating segment information divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets impairment net assetsheldforsale equity compensation plan expenses roche group notes roche group consolidated financial statements roche finance report pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results subdivisional profit elimination profit within division operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total capital expenditure research development research development costs elimination costs within division total segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets impairment net assetsheldforsale equity compensation plan expenses net operating assets millions chf assets liabilities net assets pharmaceuticals diagnostics corporate total operating nonoperating group nonoperating assets liabilities consist primarily balances related treasury pensions taxation matters roche finance report roche group notes roche group consolidated financial statementsnet operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets roche pharmaceuticals chugai elimination within division pharmaceuticals division information geographical area millions chf revenues external customers noncurrent assets royalties operating property plant goodwill sales income equipment intangible assets switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group notes roche group consolidated financial statements roche finance report supplementary unaudited information sales therapeutic areas pharmaceuticals division business areas diagnostics division given financial review sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue european union information based members eu december major customers us national wholesale distributors amerisourcebergen corp mckesson corp represented approximately billion swiss francs groups revenues amerisourcebergen corp billion swiss francs mckesson corp billion swiss francs approximately revenues pharmaceuticals operating segment residual diagnostics segment group also reported substantial revenues us national wholesale distributor cardinal health inc total three customers represented approximately quarter groups revenues chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai fully consolidated subsidiary group december groups interest chugai common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements conformity accounting principles generally accepted japan jgaap filed quarterly basis tokyo stock exchange due certain consolidation entries differences requirements international financial reporting standards ifrs jgaap differences chugais standalone results jgaap basis results chugai consolidated roche group accordance ifrs roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also right first refusal development marketing japan development compounds advanced roche roche finance report roche group notes roche group consolidated financial statementsunder rest world umbrella rights agreement signed may roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea chugai decides requires partner activities agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas smallmolecule synthetic drug research biotechnologybased drug discovery dividends dividends distributed third parties holding chugai shares totalled million swiss francs million swiss francs recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items east japan earthquake march severe earthquake tsunami struck pacific coast tohoku japan consequences chugais operations japan limited impacts disaster carefully reviewed regarding operations manufacturing processes supply chain damage chugais utsunomiya manufacturing plant resulted operations temporarily halted production products plant fully resumed end august costs recorded damage caused earthquake mainly relate utsunomiya plant consisted impairments restoration costs buildings partially damaged facilities writeoffs intermediates finished products costs shutdown net amounts received insurance costs recorded shown chugais contract manufacturers also affected earthquake result product shipment control lasted end october chugais promotional activities japan affected events cancelled employee resources diverted ensure continued product supply information flow customers factors certain negative impact chugais sales second half global issues east japan earthquake costs millions chf cost sales marketing distribution general administration total matters details chugais equity compensation plans given note roche group notes roche group consolidated financial statements roche finance report financial income financing costs financial income millions chf year ended december gains sale equity securities losses sale equity securities dividend income gains losses equity security derivatives net writedowns impairments equity securities net income equity securities interest income gains sale debt securities losses sale debt securities gains losses debt security derivatives net writedowns impairments longterm loans net interest income income debt securities expected return plan assets defined benefit plans foreign exchange gains losses net gains losses foreign currency derivatives net net foreign exchange gains losses net financial income expense total financial income financing costs millions chf year ended december interest expense amortisation debt discount gains losses debt derivatives net gains losses redemption repurchase bonds notes net time cost provisions interest cost defined benefit plans total financing costs net financial income millions chf year ended december financial income financing costs net financial income financial result treasury management financial result pension management net financial income roche finance report roche group notes roche group consolidated financial statements income taxes income tax expenses millions chf current income taxes adjustments recognised current tax prior periods deferred income taxes total income expense since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates groups average expected tax rate increased percentage points main driver increase due growth proportion groups profits generated us japan relatively higher local tax rate average group rate significant local tax rate changes main operating areas group compared groups effective tax rate increased percentage point percentage points increase average expected tax rate main driver increase nondeductible goodwill impairment groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development manufacturing tax credits us state tax impacts ther differences groups effective tax rate income tax benefits recorded respect equity compensation plans varies according price underlying equity million swiss francs million swiss francs income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefits approximately million swiss francs million swiss francs would recorded roche group notes roche group consolidated financial statements roche finance report tax effects comprehensive income millions chf pretax tax aftertax pretax tax aftertax amount benefit amount amount benefit amount availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans comprehensive income income tax assets liabilities millions chf current income taxes ssets l iabilities net current income tax assets liabilities deferred income taxes ssets l iabilities net deferred income tax assets liabilities movements amounts recorded balance sheet current income taxes shown table current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid charged credited income statement current income taxes adjustments recognised current tax prior periods charged credited equity equity compensation plans transactions shareholders currency translation effects net current income tax asset liability december roche finance report roche group notes roche group consolidated financial statementsdeferred income tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable mchf tax rate mchf tax rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred income tax liabilities established withholding tax taxes would payable unremitted earnings foreign subsidiaries amounts currently regarded permanently reinvested total foreign unremitted earnings group billion swiss francs december billion swiss francs movements amounts recorded balance sheet deferred income taxes shown table deferred income taxes movements recognised net assets liabilities millions chf property post plant intangible employment temporary equipment assets benefits differences total year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects december year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects december deferred income tax assets temporary differences mainly relates accrued liabilities provisions unrealised profit inventory roche group notes roche group consolidated financial statements roche finance report business combinations acquisitions verum effective january group acquired controlling interest privately owned company verum diagnostica gmbh verum based munich germany verum specialised coagulation diagnostics focus platelet function testing rapidly growing field coagulation market verum reported part diagnostics operating segment acquisition verum allow group gain market share coagulation segment thus strengthen leading position clinical diagnostic market purchase consideration million euros million euros paid cash million euros arose contingent consideration arrangement contingent payment arrangement based achievement performancerelated milestones range outcomes undiscounted zero million euros liability million swiss francs recognised acquisition date december based managements best estimate probability adjusted expected cash outflow arrangement purchase consideration million swiss francs allocated shown table acquisitions net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition intangible assets product intangibles use inventories deferred income taxes net assets liabilities net identifiable assets liabilities goodwill purchase consideration impact verum acquisition diagnostics division group reported results material acquisitions net cash outflow millions chf cash cash net cash consideration paid acquired company outflow acquisitions contingent consideration paid prior year acquisitions total acquisitions pvt effective april group acquired controlling interest privately owned companies pvt probenverteiltechnik gmbh based waiblingen germany pvt lab systems llc based atlanta georgia united states jointly pvt pvt global market leader providing customised automation workflow solutions vitro diagnostic testing large commercial hospital laboratories pvt reported part diagnostics operating segment acquisition complements strengthens groups portfolio clinical diagnostics market purchase consideration pvt probenverteiltechnik gmbh million euros million euros paid cash million euros arose contingent consideration arrangement purchase consideration pvt lab systems llc million us dollars paid cash contingent payment arrangement based achievement performancerelated milestones may arise end range outcomes undiscounted million euros liability million swiss francs recognised acquisition date based managements best estimate probabilityadjusted expected cash outflow arrangement december amount recognised arrangement million swiss francs based recent management estimates reflecting closing balance sheet foreign exchange rates roche finance report roche group notes roche group consolidated financial statementsmtm laboratories effective august group acquired controlling interest privately owned mtm laboratories ag mtm laboratories based heidelberg germany mtm laboratories develops vitro diagnostics detection diagnosis cancer focus cervical cancer early detection mtm laboratories reported part diagnostics operating segment acquisition complements groups portfolio offering cervical cancer testing roche tissue diagnostics business total purchase consideration million euros million euros paid cash million euros arose contingent consideration arrangement contingent payment arrangement based achievement one milestone may arise range outcomes undiscounted zero million euros liability million swiss francs recognised acquisition date based managements best estimate probabilityadjusted expected cash outflow arrangement december amount recognised arrangement million swiss francs based recent management estimates reflecting closing balance sheet foreign exchange rates anadys pharmaceuticals effective november group acquired controlling interest anadys pharmaceuticals inc anadys publicly owned us company based san diego california prior acquisition anadys listed nasdaq symbol ands anadys develops oral small molecule therapeutics potential treatment hepatitis c virus hcv infection reported part roche pharmaceuticals operating segment acquisition augment groups hcv portfolio total purchase consideration million us dollars paid cash combined purchase consideration million swiss francs consisting million swiss francs cash million swiss francs contingent consideration arrangements allocated shown table acquisitions net assets acquired millions chf carrying value fair value carrying value prior acquisition adjustments upon acquisition property plant equipment intangible assets product intangibles use product intangibles available use arketing intangibles inventories deferred income taxes cash net assets liabilities net identifiable assets liabilities goodwill purchase consideration goodwill represents control premium synergies obtained groups existing business none goodwill recognised expected deductible income tax purposes fair value net assets liabilities includes receivables fair value million swiss francs directly attributable transaction costs million swiss francs incurred acquisitions reported within general administration expenses current period part operating result roche pharmaceuticals million swiss francs diagnostics operating segment million swiss francs roche group notes roche group consolidated financial statements roche finance report acquisitions net cash outflow millions chf cash cash net cash consideration paid acquired company outflow acquisitions contingent consideration paid prior year acquisitions total contingent consideration arrangements group party certain contingent consideration arrangements arising previous business combination arrangements provisions arrangements recorded part provisions see note set table provisions contingent consideration arrangements millions chf january additional provisions created unused amounts reversed utilised year unwinding discount business combinations v erum p vt tm laboratories currency translation effects december expected outflow resources within one year one two years two three years three years total roche finance report roche group notes roche group consolidated financial statements global restructuring plans group initiated several major global restructuring plans costs incurred various plans summarised table details main elements plans disclosed following text global restructuring plans costs incurred millions chf pharma pharma rd diagnostics informatics plans total global restructuring costs e mployeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs includes closure nutley site associated infrastructure environmental remediation costs includes restructuring applied science diabetes care business areas includes operational excellence pharmaceuticals diagnostics dalcetrapib pharmaceuticals pharmaceuticals division research development reorganisation june group announced streamlining research development activities within pharmaceuticals division part plan us site nutley new jersey closed end reduction workforce approximately people research development activities currently undertaken nutley consolidated existing sites switzerland germany planned translational clinical research center alexandria centre life science manhattan us resulting savings global site consolidation related infrastructure cost bundling support functions well shifts portfolio allow reallocation resources growing number clinical programmes group continue research development activities united states genentech organisation based south san francisco affected reorganisation research development activities diagnostics division chugai also affected costs million swiss francs incurred based latest estimates cost reorganisation amount million swiss francs provisions severance payments employeerelated costs net estimated curtailment gains charge million swiss francs recorded impairments property plant equipment nutley site addition environmental remediation costs million swiss francs recorded based initial estimates additional remediation activities may needed nutley site sold impairment charges intangible assets million swiss francs recorded result portfolio prioritisation decisions linked reorganisation see note roche group notes roche group consolidated financial statements roche finance report diagnostics division applied science diabetes care restructuring initiatives announced applied science diabetes care businesses include streamlining product portfolio consolidating research development activities increasing efficiency marketing distribution operations total costs million swiss francs incurred relate employee termination site closure costs addition goodwill impairment charges million swiss francs incurred full write goodwill nimblegen acquisition resulting decision exit microarray business part reorganisation applied science business area see note million swiss francs impairment intangible assets business area see note pharmaceuticals division global informatics reorganisation first half pharmaceuticals division announced reorganisation global informatics function within division costs million swiss francs incurred mainly consisted severance payments employee related costs global restructuring plans november group announced operational excellence global restructuring plan restructuring activities substantially completed end incurred total cost billion swiss francs billion swiss francs incurred billion swiss francs incurred costs million swiss francs incurred previously announced operational excellence programme mainly employeerelated costs sales force restructuring initiatives pharmaceuticals division employee related site closure costs diagnostics division respect sites burgdorf switzerland graz austria costs million swiss francs incurred mainly employeerelated costs restructuring initiatives reorganisation costs pharmaceuticals division impairment manufacturing site boulder colorado sold august losses divestment research development site madison wisconsin research site kulmbach germany costs partially offset gain disposal site palo alto california sold june second quarter pharmaceuticals division initiated detailed review following announcement results second interim analysis dalcetrapib daloutcomes phase iii trial subsequent termination daloutcomes trial studies dalheart programme restructuring costs million swiss francs incurred consist remaining trial costs writeoffs inventories property plant equipment additionally million swiss francs expensed writeoff previously acquired intangible assets see note roche finance report roche group notes roche group consolidated financial statementsglobal restructuring plans summary costs incurred millions chf employeerelated costs ermination costs pensions postemployment benefits employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment gains losses disposal property plant equipment site closure costs total site closure costs divestment products businesses impairment net assetsheldforsale gains losses divestment businesses total costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental costs total costs roche group notes roche group consolidated financial statements roche finance report global restructuring plans classification costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total cost sales p harmaceuticals iagnostics marketing distribution p harmaceuticals iagnostics research development p harmaceuticals iagnostics general administration p harmaceuticals iagnostics c orporate total total operating segment r oche pharmaceuticals c hugai iagnostics c orporate total employee benefits employee remuneration millions chf wages salaries social security costs defined contribution postemployment plans operating expenses defined benefit postemployment plans equity compensation plans termination costs employee benefits employee remuneration included operating results expected return plan assets defined benefit postemployment plans interest cost defined benefit postemployment plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits charges employee benefits operating results included relevant expenditure line function expected return plan assets interest cost defined benefit plans included part financial income financing costs respectively see note roche finance report roche group notes roche group consolidated financial statements pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups long term financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefits consist mostly postretirement healthcare life insurance schemes principally united states postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans even groups potential obligation relatively minor relatively remote possibility arising consequently groups postemployment benefit plans classified defined benefit plans purpose financial statements defined contribution plans defined contribution plans typically consist payments employees group funds administered third parties payments group million swiss francs million swiss francs assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions defined benefit plans groups major defined benefit plans located switzerland united states germany united kingdom japan plans usually established trusts independent group funded payments group employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources current past service costs charged appropriate income statement heading within operating results pension plan administration funding overseen corporate level settlement gains losses resulting changes funding arrangements reported general administration expenses within corporate segment expected returns plan assets interest costs charged financial income financing costs respectively actuarial gains losses recorded directly comprehensive income recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit recognition assets defined benefit plans recorded directly comprehensive income defined benefit plans income statement millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total current service cost past service cost gain loss curtailment gain loss settlement total operating expenses expected return plan assets interest cost total financial income expense total expense recognised income statement roche group notes roche group consolidated financial statements roche finance report funding groups various defined benefit plans overseen corporate level qualified independent actuaries carry valuations regular basis major plans annually reporting date funded plans usually trusts independent groups finances net assetliability recognised groups balance sheet corresponds overunder funding plan adjusted unrecognised past service costs unfunded plans group meets pension obligations directly financial resources liability defined benefit obligation recorded groups balance sheet pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan amounts recognised balance sheet postemployment benefits predominantly noncurrent reported non current assets liabilities defined benefit plans funding status millions chf funded unfunded funded unfunded plans plans total plans plans total fair value plan assets defined benefit obligation funding unrecognised past service costs limit asset recognition reimbursement rights net recognised asset liability reported balance sheet postemployment benefit assets postemployment benefit liabilities net recognised asset liability detailed information plan assets defined benefit obligation given defined benefit plans fair value plan assets reimbursement rights millions chf fair value plan assets reimbursement rights january expected return plan assets actuarial gains losses currency translation effects employer contributions employee contributions benefits paid funded plans past service cost divestment subsidiaries curtailments settlements december roche finance report roche group notes roche group consolidated financial statementsdefined benefit plans composition plan assets millions chf shares equity instruments bonds debentures debt instruments property cash investments roche group nonvoting equity securities roche group debt instruments roche group shares total investments consist mainly equity funds alternatives mortgages commodities insurance policies defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost employee contributions actuarial gains losses currency translation effects benefits paid funded plans benefits paid unfunded plans past service cost divestment subsidiaries curtailments settlements december actuarial assumptions actuarial assumptions unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates returns investments salary benefit levels inflation rates costs medical benefits group operates defined benefit plans many countries actuarial assumptions vary based upon local economic social conditions demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity roche group notes roche group consolidated financial statements roche finance report mortality tables used major schemes country mortality table germany heubeck tables g japan mhlw switzerland bvg generational tables united kingdom snal rated years female nonpensioners years members future improvements cmi core projection longterm improvement united states rp projected years rates employee turnover disability early retirement based historical behaviour within group companies financial assumptions based market expectations period obligations settled ranges assumptions used actuarial valuations significant plans countries stable currencies interest rates shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates return plan assets expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates used calculate discounted present value defined benefit obligation determined reference market yields highquality corporate bonds government bonds countries deep market corporate bonds currency term bonds consistent obligation discounted interest cost included income statement calculated multiplying discount rate defined benefit obligation defined benefit plans sensitivity discount rate millions chf current service cost interest cost defined benefit obligation expected returns plan assets based market expectations expected returns assets funded plans duration related obligation takes account split plan assets equities bonds property investments calculation includes assumptions concerning expected dividend interest income realised unrealised gains plan assets taxes administration costs borne plan based longterm market expectations actual performance continually monitored corporate management due longterm nature obligations assumptions used matters returns investments may necessarily consistent recent historical patterns expected return plan assets included income statement calculated multiplying expected rate return fair value plan assets difference expected return actual return twelvemonth period actuarial gainloss recorded directly comprehensive income actual return plan assets gain million swiss francs gain million swiss francs roche finance report roche group notes roche group consolidated financial statementsexpected rates salary increases used calculate defined benefit obligation current service cost included income statement based latest expectation historical behaviour within group companies expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances medical cost trend rates used calculate defined benefit obligation current service cost included income statement postemployment medical plans take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments united states effect one percentage point increase decrease medical cost trend rate shown defined benefit plans sensitivity medical cost trend rate millions chf current service cost interest cost defined benefit obligation historical summary fiveyear summary groups defined benefit plans shown table defined benefit plans historical information millions chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation experience adjustments actuarial gains losses plan assets experience adjustments change actuarial assumptions actuarial gains losses plan liabilities cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow roche group notes roche group consolidated financial statements roche finance report based recent actuarial valuations group expects employer contributions funded plans approximately million swiss francs includes estimated million swiss francs additional contributions benefits paid unfunded plans estimated approximately million swiss francs amounts recorded comprehensive income actuarial gains losses recognised statement comprehensive income follows accumulated actuarial gains losses pretax millions chf january actuarial gains losses recognised plan assets liabilities actuarial gains losses recognised reimbursement rights december recognition pension assets limited total present value future refunds plans reductions future contributions plans cumulative unrecognised past service costs adjustments arising limit asset recognition recorded directly comprehensive income follows limit asset recognition pretax millions chf january increase decrease asset limit recognised year december roche finance report roche group notes roche group consolidated financial statements employee stock options equity compensation plans group operates several equity compensation plans including separate plans chugai ifrs sharebased payment requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses share option plans roche option plan total share option plans equity compensation plans bonus stock awards roche connect roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan roche stock appreciation rights chugai equity compensation plans total equity compensation plans total operating expenses e quitysettled c ashsettled roche group notes roche group consolidated financial statements roche finance report cash inflow outflow equity compensation plans millions chf equitysettled equity compensation plans roche option plan exercises chugai equitycompensation plan exercises roche connect costs total equitysettled equity compensation plans cash outflow transactions equity instruments total cash inflow outflow equitysettled equity compensation plans net transactions equity instruments cashsettled plans included part movements net working capital roche stock appreciation rights net cash outflow transactions equity instruments mainly arises sales purchases nonvoting equity securities genussscheine derivative instruments thereon held groups potential conversion obligations may arise groups equitysettled equity compensation plans derivative instruments mainly consist call options exercisable time maturity see note roche longterm group implemented new global longterm incentive programme available certain directors management employees selected discretion group programme consists stock settled stock appreciation rights ssars group alternative granting awards existing roche option plan following integration genentech group also established restricted stock unit rsu plan first awards plan made september employees genentech ssars issued accordance roche ssar plan regulations million ssars available issuance tenyear period rsus issued accordance roche restricted stock unit plan regulations million nonvoting equity securities available issuance tenyear period remuneration committee determines number nonvoting equity securities available plans year plan regulations ssar rsu plans restated amended effective january details plans given relevant sections share option plans roche option plan awards plan give employees right purchase nonvoting equity securities exercise price specified grant date roche option plan regulations restated amended effective january referred roche option plan options nontradable equitysettled awards sevenyear duration vest phased basis three years subject continued employment roche option plan includes provisions respect consequences termination employment effect certain corporate transactions authority remuneration committee executive committee interpret administer plan group covers obligations purchasing nonvoting equity securities derivatives thereon see note introduction roche longterm number options granted roche option plan significantly reduced eligible employees receive roche stocksettled stock appreciation rights instead roche finance report roche group notes roche group consolidated financial statementsroche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable number weighted average weighted average weighted average outstanding years remaining exercise price number exercisable exercise price year grant thousands contractual life chf thousands chf total issues roche option plan number options granted underlying equity roche nonvoting equity securities currency swiss francs vesting period progressively years contractual life years weighted average fair value options issued option pricing model used binomial inputs option pricing model share price grant date e xercise price e xpected volatility expected dividend yield early exercise factor expected exit rate roche group notes roche group consolidated financial statements roche finance report volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour exercise share options weighted average share price roche nonvoting equity securities year swiss francs equity compensation plans bonus stock awards certain members corporate executive committee granted bonus stock awards lieu part cashsettled bonus financial year issued end april total fair value million swiss francs number awards fair value per award calculated grant date roche connect programme enables employees worldwide except united states certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually programme operational since october administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million year cost plan million swiss francs million swiss francs reported within relevant expenditure line function roche stocksettled stock appreciation rights introduction roche longterm group offers stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date ssar plan regulations restated amended effective january referred roche ssar plan roche ssar plan million ssars available issuance tenyear period rights nontradable equitysettled awards sevenyear duration vest phased basis three years roche ssar plan also includes provisions respect consequences termination employment effect certain corporate transactions authority remuneration committee executive committee interpret administer plan within meaning section title california corporations code sections title california code regulations approval annual financial statements constitutes approval roche ssar plan described annual financial statements majority roche holding ltds outstanding securities entitled vote group covers obligations purchasing nonvoting equity securities derivatives thereon see note roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche finance report roche group notes roche group consolidated financial statementsroche ssars terms rights outstanding december rights outstanding rights exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total weighted average fair value rights granted calculated using binomial model inputs model consistent used roche option plan awards resulting weighted average fair value per right swiss francs giving total fair value million swiss francs charged vesting period three years roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period rsu plan regulations restated amended effective january referred roche rsu plan roche rsu plan million nonvoting equity securities available issuance tenyear period awards nontradable represent right receive nonvoting equity securities generally vest three year period subject performance conditions roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted addition roche rsu plan includes provisions respect consequences termination employment effect certain corporate transactions authority remuneration committee executive committee interpret administer plan provisions consistent terms applicable california securities laws within meaning section title california corporations code sections title california code regulations approval annual financial statements constitutes approval roche rsu plan described annual financial statements majority roche holding ltds outstanding securities entitled vote roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december exercisable roche group notes roche group consolidated financial statements roche finance report roche performance share plan group offers future nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers nontradable equity settled awards programme established beginning currently operates annual threeyear cycles roche performance share plan regulations restated amended effective january referred roche psp plan roche psp plan includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted addition roche psp plan includes provisions respect consequences termination employment effect certain corporate transactions authority remuneration committee executive committee interpret administer plan terms currently outstanding awards set table amount nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors award result zero two nonvoting equity securities depending upon achievement performance targets roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years years allocated recipients feb feb feb fair value per unit grant chf total fair value grant chf millions weighted average fair value awards granted calculated using monte carlo simulation input parameters model covariance matrix roche individual companies peer group based threeyear history riskfree rate minus valuation also takes account defined rank performance structure determines payout plan chugai stock acquisition rights chugai adopted stock acquisition rights programme programme allows granting rights employees directors chugai rights issued non tradable equitysettled awards tenyear duration vest two years right entitles holder purchase chugai shares specified exercise price total fair value rights issued equivalent million swiss francs million swiss francs calculated using binomial model chugai retirement stock acquisition rights first time chugai issued stock acquisition rights lieu retirement gratuities system directors abolished rights issued thirtyyear duration vest upon holders retirement director chugai right entitles holder purchase chugai shares exercise price japanese yen total fair value rights issued equivalent million swiss francs million swiss francs calculated using binomial model roche finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment movements carrying value assets millions chf buildings machinery land construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january additions disposals business combinations divestment subsidiaries transfers reclassification assetsheldforsale depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january additions disposals business combinations transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value roche group notes roche group consolidated financial statements roche finance report impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors changes planned use buildings machinery equipment closure facilities presence absence competition technical obsolescence could result shortened useful lives impairment impairment charges million swiss francs million swiss francs reported part cost sales million swiss francs none marketing distribution million swiss francs million swiss francs research development million swiss francs general administration none income received insurance companies respect impairments property plant equipment million swiss francs borrowing costs capitalised property plant equipment none leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases million swiss francs million swiss francs net book value assets million swiss francs million swiss francs carrying value leasing obligation million swiss francs million swiss francs reported part debt see note finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value future payments minimum lease payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted operating leases group companies party number operating leases mainly plant machinery including motor vehicles certain shortterm property rentals arrangements impose significant restrictions group total operating lease rental expense million swiss francs million swiss francs operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method roche finance report roche group notes roche group consolidated financial statementsfinance leases future minimum lease payments noncancellable leases millions chf present value future gross investment lease minimum lease payments within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments million swiss francs million swiss francs contingent rents recognised income operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straightline basis december machinery equipment original cost million swiss francs million swiss francs net book value million swiss francs million swiss francs leased third parties contingent rent recognised income operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling billion swiss francs billion swiss francs roche group notes roche group consolidated financial statements roche finance report goodwill goodwill movements carrying value assets millions chf january cost accumulated impairment net book value year ended december january business combinations divestment subsidiaries impairment charge currency translation effects december cost accumulated impairment net book value allocated following cashgenerating units roche pharmaceuticals chugai total pharmaceuticals division diabetes care professional diagnostics molecular diagnostics applied science tissue diagnostics strategic goodwill held divisional level allocated business areas total diagnostics division goodwill arising investments associates classified part investments associates see note goodwill impairment testing pharmaceuticals division divisions subdivisions cashgenerating units used testing goodwill chugai recoverable amount based fair value less costs sell determined reference publicly quoted share prices chugai shares roche pharmaceuticals recoverable amount used impairment testing based value use cash flow projections used roche pharmaceuticals impairment testing based recent business plans approved management business plans include managements latest estimates sales volume pricing production operating costs assumes significant changes organisation roche finance report roche group notes roche group consolidated financial statementsthe business plans projected five years valuations include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data capital markets including government twentyyear bonds weighted average tax rate used calculations corresponding pretax discount rate diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division recoverable amount used impairment testing based value use cash flow projections based recent business plans approved management business plans include managements latest estimates sales volume pricing production operating costs business plans assume significant changes organisation beyond applied science restructuring explained business plans projected five years except tissue diagnostics business area projected ten years reflecting longterm nature business valuations include terminal value beyond years assuming growth discount rate used based aftertax rate derived capital asset pricing model using data capital markets including government twentyyear bonds weighted average tax rate used calculations corresponding pretax discount rate diagnostics division announced several global restructuring initiatives disclosed note part plan streamlining product portfolio applied science business division exiting microarray business microarray business acquired acquisition nimblegen result decision microarray business longer considered part applied science business area cashgenerating unit assessing goodwill impairment given plan exit microarray business goodwill arose nimblegen acquisition considered fully impaired charge million swiss francs recorded remaining goodwill million swiss francs applied science business area supported value use ongoing business dependent success plan streamline product portfolio goodwill sensitivity analysis management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount rate combined decreasing forecast cash flows results sensitivity analyses demonstrated changes key assumptions would cause carrying value goodwill exceed recoverable amount roche group notes roche group consolidated financial statements roche finance report intangible assets intangible assets movements carrying value assets millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total january cost accumulated amortisation impairment net book value year ended december january business combinations additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment r oche pharmaceuticals c hugai iagnostics total group year ended december january business combinations additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocation operating segment r oche pharmaceuticals c hugai iagnostics total group roche finance report roche group notes roche group consolidated financial statementssignificant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use tanox acquisition roche pharmaceuticals years corangeboehringer mannheim acquisition diagnostics years ventana acquisition diagnostics years product intangibles available use intermune alliance roche pharmaceuticals na ventana acquisition diagnostics na classification amortisation impairment expenses millions chf amortisation impairment amortisation impairment cost sales p harmaceuticals iagnostics marketing distribution iagnostics research development p harmaceuticals iagnostics general administration p harmaceuticals total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases december carrying value assets pharmaceuticals division million swiss francs amount approximately represents projects potential decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project question result commercialised product intangible asset impairment impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lower anticipated sales products capitalised rights could result shortened useful lives impairment intangible asset impairment charges total impairment charges million swiss francs million swiss francs roche pharmaceuticals operating segment million swiss francs diagnostics operating segment roche group notes roche group consolidated financial statements roche finance report pharmaceuticals division impairment charges totalling million swiss francs arose various global restructuring initiatives disclosed note following recent dalcetrapib trial results impairment charges million swiss francs incurred respect previously acquired intangible assets additionally impairment charges million swiss francs recorded following portfolio prioritisation decision part reorganisation research development pharmaceuticals division assets concerned yet amortised fully written impairment charges million swiss francs recorded following portfolio prioritisation decision pharmaceuticals division relates decision return global rights monoclonal antibody rg antiplgf mab alliance partners assets concerned yet amortised fully written charges impairment charges million swiss francs recorded following latest clinical data assessment project acquired part marcadia acquisition assets concerned yet amortised written recoverable value million swiss francs following recent clinical data impairment charges million swiss francs recorded respect projects collaboration alliance partners assets concerned yet amortised fully written charges addition impairment charges million swiss francs recorded relate decision stop development one compound alliance partner assets concerned amortised fully written charges diagnostics division impairment charges million swiss francs recorded includes million swiss francs global restructuring initiatives applied science diabetes care businesses see note assets concerned partly amortised written recoverable value million swiss francs intangible asset impairment charges total impairment charges million swiss francs million swiss francs roche pharmaceuticals operating segment million swiss francs diagnostics operating segment pharmaceuticals division impairment charge million swiss francs recorded related decision stop development project acquired business combination outlicensed alliance partner assets concerned partly amortised written recoverable value million swiss francs charges million swiss francs recorded resulting portfolio prioritisation decisions projects acquired separately part business combination assets concerned yet amortised fully written charges diagnostics division impairment charge million swiss francs recorded mainly respect intangible assets use followed regular updating divisions business plans technology assessments second half assets concerned written recoverable amount million swiss francs potential commitments alliance collaborations group party inlicensing similar arrangements alliance partners arrangements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration agreements groups current estimate future thirdparty commitments payments set table figures undiscounted risk adjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses roche finance report roche group notes roche group consolidated financial statementspotential future thirdparty collaboration payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total associates groups investments associates accounted using equity method goodwill arising investments associates classified part investments associates investments associates millions chf january share net income currency translation effects december group significant investments associates material transactions group associates additional information associates given note financial longterm assets financial longterm assets millions chf availableforsale investments heldtomaturity investments loans receivable longterm trade receivables restricted cash total financial longterm assets longterm employee benefits total longterm assets financial longterm assets held strategic purposes classified noncurrent availableforsale investments mainly equity investments primarily investments private biotechnology companies kept part groups strategic alliance efforts unquoted equity investments classified availableforsale measured cost fair value measured reliably carrying value equity investments held cost million swiss francs million swiss francs million swiss francs loans receivable comprise loans third parties term one year roche group notes roche group consolidated financial statements roche finance report inventories inventories millions chf raw materials supplies work process intermediates finished goods less provision slowmoving obsolete inventory total inventories expenses relating inventories expensed cost sales totalled million swiss francs million swiss francs accounts receivable accounts receivable millions chf trade accounts receivable notes receivable receivables allowances doubtful accounts chargebacks allowances total accounts receivable december accounts receivable include amounts denominated us dollars equivalent billion swiss francs billion swiss francs billion swiss francs amounts denominated euros equivalent billion swiss francs billion swiss francs billion swiss francs allowances doubtful accounts receivable movements recognised liability millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december expenses relating bad debts expensed marketing distribution totalled million swiss francs million swiss francs significant concentrations within trade receivables counterparty credit risk described note roche finance report roche group notes roche group consolidated financial statements current assets current assets millions chf accrued interest income derivative financial instruments restricted cash receivables total financial current assets prepaid expenses taxes recoverable assets total nonfinancial current assets total current assets derivative financial instrument assets primarily related hedges nonus dollardenominated bonds notes issued finance genentech transaction increase compared december mainly due strengthening euro compared us dollar marketable securities marketable securities millions chf financial assets fairvaluethroughprofitorloss bonds debentures total financial assets fairvaluethroughprofitorloss heldtomaturity financial assets money market instruments time accounts three months total heldtomaturity financial assets availableforsale financial assets hares bonds debentures money market instruments time accounts three months ther investments total availableforsale financial assets total marketable securities marketable securities held fund management purposes classified current primarily denominated swiss francs us dollars euros investments held strategic purposes classified noncurrent see note roche group notes roche group consolidated financial statements roche finance report bonds debentures carrying values contracted maturity debt securities shown bonds debentures millions chf contracted maturity within one year one five years five years total bonds debentures money market instruments contracted mature within one year december cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents accounts payable accounts payable millions chf trade accounts payable taxes payable dividends payable accounts payable total accounts payable accrued current liabilities accrued liabilities current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments accrued liabilities total accrued current liabilities roche finance report roche group notes roche group consolidated financial statements derivative financial instruments group uses derivative financial instruments part risk management activities discussed note derivative financial instruments carried fair value methods used determining fair value described note derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts c rosscurrency swaps ther interest rate derivatives waps ther derivatives total derivative financial instruments hedge accounting groups accounting policy hedge accounting described note requires qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement described note group financial risk management policies foreign exchange risk interest rate risk market risk credit risk liquidity risk deemed appropriate certain risks managed using derivatives many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income group generally limits use hedge accounting certain significant transactions consequently december group fair value hedges cash flow hedges hedges net investment foreign entity meet strict requirements qualify hedge accounting apart described cash flow hedges group issued bonds notes finance genentech transaction see note bonds notes denominated euros sterling group entered crosscurrency swaps hedge foreign exchange interest rate risk december instruments designated qualify hedge accounting recorded assets fair value million swiss francs assets million swiss francs ineffective portion group entered foreign exchange forward contracts hedge part foreign translation exposure euros december instruments designated qualify hedge accounting recorded liabilities fair value million swiss francs ineffective portion roche group notes roche group consolidated financial statements roche finance report expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table expected cash flows qualifying cash flow hedges millions chf total months months months years years years years years year ended december cash inflows cash outflows total year ended december cash inflows cash outflows total undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity expected cash flows qualifying cash flow hedges impact profit loss millions chf total months months months years years years years years year ended december cash inflows cash outflows total year ended december cash inflows cash outflows total changes hedging reserve within equity shown note fair value hedges group entered interest rate swaps hedge fixedterm debt instruments instruments designated qualified fair value hedges recorded balance sheet december assets fair value million swiss francs assets million swiss francs loss million swiss francs recorded interest rate swaps gain million swiss francs fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments group equity investments various biotechnology companies subject greater risk market fluctuation stock market general manage part exposure group entered forward contracts designated qualify fair value hedges december instruments recorded liabilities fair value million swiss francs liabilities million swiss francs loss million swiss francs recorded forward contracts loss million swiss francs result forward contracts offset changes fair value hedged equity investments group uses derivatives designated qualifying hedge relationship manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options roche finance report roche group notes roche group consolidated financial statements provisions contingent liabilities provisions movements recognised liabilities millions chf legal environmental restructuring employee provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised year unwinding discount business combinations cquired companies c ontingent consideration contingent consideration utilisation divestment subsidiaries currency translation effects december c urrent portion n oncurrent portion total provisions year ended december january additional provisions created unused amounts reversed utilised year unwinding discount business combinations cquired companies c ontingent consideration contingent consideration utilisation currency translation effects december c urrent portion n oncurrent portion total provisions expected outflow resources within one year one two years two three years three years total provisions roche group notes roche group consolidated financial statements roche finance report legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies majority cash outflows matters expected occur within next one three years although dependent development various litigations significant provisions discounted time value money material legal expenses totalled million swiss francs million swiss francs reflect recent developments various legal matters details major legal cases outstanding disclosed environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict estimated timings cash outflows shown table significant provisions discounted time value money material disclosed note restructuring plan streamline research development activities within pharmaceuticals division includes closure us site nutley new jersey expense million swiss francs recorded based estimates additional remediation activities may needed nutley site sold expenses also recorded increase estimated remediation costs landfill site near grenzach germany used manufacturing operations closed years ago restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain global basis shown table provisions discounted time value money material matters restructuring provisions created primarily related plan streamline research development activities within pharmaceuticals division mainly related closure us site nutley new jersey employee provisions mostly relate certain employee benefit obligations sabbatical leave longservice benefits timings cash outflows reasonably estimated based past performance shown table significant provisions discounted time value money material provisions timings cash outflows nature uncertain best estimates shown table significant provisions discounted time value money material provisions millions chf sales returns contingent consideration items total provisions roche finance report roche group notes roche group consolidated financial statementscontingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note pharmaceuticals legal cases accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions united states elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders december hlr defending approximately actions involving approximately plaintiffs brought various federal state courts throughout united states personal injuries allegedly resulting use accutane actions allege ibd result accutane use june hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product united states actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation united states district court middle district florida tampa division since july district court granted summary judgment favour hlr federal ibd cases proceeded since august rulings affirmed united states court appeals eleventh circuit plaintiffs appealed multiple recently filed matters remain pending actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county december juries superior court ruled favour plaintiff eight cases assessing total compensatory damages totalling million us dollars ruled favour hlr four cases eight cases originally ruled favour plaintiff superior court hlr process appealing two cases million us dollars one case scheduled retrial april million us dollars posttrial briefing ongoing two cases million us dollars three cases verdicts reversed favour hlr million us dollars may trial involving four plaintiffs reached defence verdicts two cases awarded compensatory damages million us dollars two cases cases posttrial briefing august new jersey appellate division reversed three verdicts favour plaintiffs amount million us dollars directed final judgment entered hlr court held controlling florida case law hlr entitled judgment prescribing physicians testified would still prescribed accutane even face plaintiffs proposed different warnings thus plaintiffs could establish respective cases new jersey supreme court declined plaintiffs request review decision additional trials may scheduled individual trial results depend variety factors including many unique particular case therefore trial results date may predictive future trial results group continues defend vigorously remaining personal injury cases claims roche group notes roche group consolidated financial statements roche finance report cabilly patents october glaxo group limited smithkline beecham corporation glaxosmithkline llc collectively gsk filed patent lawsuit genentech city hope us district court southern district florida lawsuit related us patent cabilly ii patent coowned genentech city hope february gsk dismissed florida lawsuit entirety filed related action day us district court northern district california subsequently transferred central district california lawsuit gsk seeking declaratory judgment patent invalidity unenforceability regard cabilly ii patent patent noninfringement regard gsks arzerra product first half additional lawsuits genentech gsk andor human genome sciences inc hgs involving cabilly ii patent related us patent cabilly iii patent filed us district courts district delaware central district california lawsuits filed delaware subsequently transferred central district california additional lawsuits included claims gsk andor hgs cabilly patents infringed invalid unenforceable genentech violated antitrust unfair competition laws laws claims genentech gsks arzerra product gsks hgss benlysta product infringed cabilly patents march parties agreed settlement claims lawsuits relating arzerra product december parties agreed settlement remaining claims lawsuits including related benlysta product matters concluded rituxan arbitration sanofihoechst october genentech biogen idec inc filed complaint sanofiaventis deutschland gmbh sanofi sanofiaventis us llc sanofiaventis us inc northern district california seeking declaratory judgment certain genentech products including rituxan infringe sanofis us patents declaratory judgment patents invalid also october sanofi filed suit genentech biogen idec eastern district texas lufkin division claiming rituxan least eight genentech products infringe patents sanofi requested preliminary permanent injunctions compensatory exemplary damages relief subsequently texas california cases consolidated northern district california march district court ruled matter law genentech biogen idec infringe asserted patent claims may sanofi filed notice appeal courts noninfringement ruling claim construction order appellate court affirmed district courts judgment rituxan product infringe claims either patents addition october hoechst gmbh filed icc international court arbitration paris request arbitration genentech relating terminated agreement one hoechsts predecessors genentech pertained patents related patents outside united states hoechst seeking payment royalties sales genentech products damages breach contract relief june icc arbitrator issued intermediate decision indicating rituxan covered terminated agreement ordering genentech produce certain rituxan sales information december october group expects arbitrator would use information possibly information determine amount damages awarded hoechst december group recorded back royalty expense million swiss francs net assumed reimbursement portion groups obligation copromotion partner us corresponding amount accrued liabilities december amount accrued continues represent managements best estimate compensatory damages including interest may awarded hoechst based financial terms terminated agreement final amount decision may vary amounts provided nature andor extent damages awarded hoechst differ groups estimate genentech successfully challenges arbitrators decision july genentech filed declaration appeal court appeal paris initiate legal proceedings challenging arbitrators decision arbitrator subsequently stated parties june decision decide operative part underlying issue liability respect rituxan light statement genentech pursue previously filed action challenge arbitrators decision without prejudicing ability bring challenge future march genentech completed briefing liability amount owed license agreement arbitrator find liability september arbitrator issued decision indicating genentech liable hoechst certain damages yet determined november arbitrator held hearing amount damages genentech may owe hoechst arbitrator yet issued decision regarding damages december genentech filed declaration appeal court appeal paris initiate legal proceedings challenging arbitrators decision roche finance report roche group notes roche group consolidated financial statementson may genentech filed motion us district court seeking enjoin sanofi affiliates eg hoechst pursuing award icc arbitration would undermine contrary us courts final judgment infringement district court denied motion genentech appealed us court appeals federal circuit appeal hearing held january decision expected later outcome matters determined time average wholesale prices litigation hlr roche laboratories inc rli along approximately brand generic pharmaceutical companies named defendants several legal actions united states relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending one awp action filed state new jersey discovery currently pending case hlr rli vigorously defending matter outcome matter determined time brand name prescription drugs litigations hlr along various branded pharmaceutical companies named defendant several legal actions united states brought retail pharmacies relating discounting practices brand name prescription drugs bnpd bnpd litigations plaintiffs allege denied discounts certain prescription drugs offered mail order managed care entities denial claimed violation robinsonpatman act rpa rpa federal law prohibits unlawful price discrimination addition plaintiffs alleged defendants conspired refusal offer certain discounts conspiracy claims defendants previously settled rpa claims remaining litigated december hlr rli successfully obtained dismissals bnpd cases longer defending matters matter concluded university pennsylvania litigation may genentech filed patent lawsuit university pennsylvania us district court northern district california lawsuit related us patent sought declaratory judgment patent noninfringement invalidity regard patent july university counterclaimed genentech infringement patent seeking unspecified damages based sales herceptin may court issued claim construction order construing certain terms used claims patent june parties entered binding term sheet settle litigation parties dismissed case stipulation matter concluded pdl litigation august pdl biopharma pdl filed complaint genentech nevada state court seeking judicial declaration concerning genentechs obligation pay royalties certain exus sales herceptin avastin xolair lucentis agreement parties september pdl filed first amended complaint asserting additional claims genentech including breach contract breach implied covenant good faith fair dealing pdl also asserted new claims roche novartis intentional interference contractual relations addition declaratory relief pdl seeking monetary damages including compensatory liquidated damages november genentech roche filed motion dismiss failure state claim roche filed additional motion dismiss lack personal jurisdiction july court denied motions pdl settled claim novartis fact discovery parties ongoing expected completed march trial currently scheduled october addition litigation pdl conducted royalty audit related sales avastin herceptin lucentis xolair raptiva years october group received pdl copy independent auditors final audit report audit report indicates pdls interpretation certain contract terms genentech owes pdl additional royalties audit period interpretation genentech may owe additional royalties years subsequent audit period group disputes pdls interpretation relevant contract terms believe additional royalties owed outcome matters determined time roche group notes roche group consolidated financial statements roche finance report gsk litigation september gsk genentech filed patent lawsuits one another case gsk also roche holding ltd us district courts district delaware northern district california respectively lawsuits concern gsks us patent nos gsk asserted claims genentech roche alleging infringement patents certain therapeutic antibody products although complaint specifically refers herceptin lawsuit genentech seeking judicial declaration noninfringement certain genentech products delaware action november genentech filed motion dismiss failure state claim motion transfer case california roche filed motion dismiss lack personal jurisdiction parties subsequently stipulated roches dismissal genentech remains party march delaware court denied genentechs motion transfer case california june parties agreed dismiss california action without prejudice case proceed delaware outcome matters determined time boniva litigation hlr genentech various roche affiliates collectively roche named defendants numerous legal actions united states canada relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw onj atypical femoral fractures december hlr defending approximately actions involving approximately plaintiffs brought federal state courts throughout united states one action brought court queens bench province saskatchewan canada personal injuries allegedly resulting use boniva cases early discovery stages litigation individual trial results depend variety factors including many unique particular case roche vigorously defending matters outcome matters determined time ema investigation october european medicines agency ema announced would start infringement procedure investigate allegations regarding alleged breach medicines safety reporting obligations relation centrally authorised medicines investigation take months conclude based data reviewed submitted ema date impact safety profiles products found date ema health authorities confirmed medicines remain authorised without changes treatment advice patients healthcare professionals corrective preventative actions resulting inspections completed newly defined processes implemented become routine practice outcome investigation determined time diagnostics legal cases marsh supermarkets litigation july marsh supermarkets inc marsh filed breach contract suit roche diagnostics operations inc rdo lawsuit relates termination sublease agreement building rdo extensive argument bench trial hamilton superior court judge awarded marsh damages amounting million us dollars accrued legal provision rdo appealed judgment decision expected first half outcome appeal determined time noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities longterm liabilities consist mainly accrued longterm employee benefits roche finance report roche group notes roche group consolidated financial statements debt debt movements carrying value recognised liabilities millions chf january proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt gains losses redemption repurchase bonds notes net amortisation debt discount foreign currency transaction gains losses net currency translation effects december consisting bonds notes c ommercial paper amounts due banks financial institutions finance lease obligations ther borrowings total debt reported l ongterm debt hortterm debt total debt fair value bonds notes billion swiss francs billion swiss francs billion swiss francs fair value total debt billion swiss francs billion swiss francs billion swiss francs calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods pledges groups assets connection debt roche group notes roche group consolidated financial statements roche finance report bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollardenominated notes floating rate months libor notes due february principal million us dollars na us dollardenominated notes fixed rate notes due march principal billion us dollars outstanding billion us dollars isin usual usaq notes due march principal billion us dollars isin usuam usas na notes due march principal billion us dollars isin usuan usau na european medium term note programme fixed rate notes due march principal billion euros outstanding billion euros isin xs notes due march principal billion pounds sterling outstanding billion pounds sterling isin xs notes due march principal billion euros outstanding billion euros isin xs notes due june principal billion euros isin xs na notes due march principal billion euros isin xs notes due august principal million pounds sterling outstanding million pounds sterling isin xs na swiss franc bonds floating rate months libor notes due september principal billion swiss francs na swiss franc bonds bonds due march principal billion swiss francs isin ch bonds due march principal billion swiss francs isin ch na bonds due september principal billion swiss francs isin ch na bonds due september principal billion swiss francs isin ch na genentech senior notes senior notes due july principal billion us dollars isin usag na senior notes due july principal million us dollars isin usac na total roche finance report roche group notes roche group consolidated financial statementsbonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds pound sterling notes total unamortised discount issuance bonds notes group raised net proceeds approximately billion swiss francs series debt offerings described newly issued debt senior unsecured guaranteed roche holding ltd european medium term notes march group issued eurodenominated fixed rate notes terms proceeds notes follows issuance european medium term notes effective interest principal amount net proceeds rate eur millions chf millions fixed rate eur notes due total swiss francdenominated bonds march group completed offering swiss francdenominated fixed rate floating rate bonds terms proceeds bonds follows issuance swiss francdenominated bonds effective interest principal amount net proceeds rate chf millions chf millions floating rate months libor bonds due fixed rate bonds due fixed rate bonds due total issuance bonds notes group issue bonds notes roche group notes roche group consolidated financial statements roche finance report redemption repurchase bonds notes redemption swiss francdenominated notes due date march group redeemed notes principal amount outstanding million swiss francs original issue amount plus accrued original issue discount effective interest rate notes cash outflow million swiss francs gain loss recorded redemption partial repurchase eurodenominated notes march group completed tender offer nominal amount million euros fixed rate notes due march total principal amount outstanding million euros cash outflow million swiss francs plus accrued interest loss repurchase notes million swiss francs november group completed tender offer nominal amount million euros fixed rate notes due march total principal amount outstanding million euros cash outflow million swiss francs plus accrued interest loss repurchase notes million swiss francs addition group terminated currency swaps used hedge foreign currency risk eurodenominated notes created additional loss million swiss francs reflecting change fair value hedging derivatives due changes interest rates total loss repurchases million swiss francs recorded within financing costs see note effective interest rate notes repurchased partial repurchase eurodenominated notes november group completed tender offer nominal amount million euros fixed rate notes due march total principal amount outstanding billion euros cash outflow million swiss francs plus accrued interest loss repurchase notes million swiss francs addition group terminated currency swaps used hedge foreign currency risk eurodenominated notes created additional loss million swiss francs reflecting change fair value hedging derivatives due changes interest rates total loss repurchase million swiss francs recorded within financing costs see note effective interest rate notes repurchased early redemption us dollardenominated notes december group resolved exercise option call redemption entire outstanding us dollardenominated fixed rate notes due march group redeem remaining outstanding principal billion us dollars march amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal us treasury rate determined independent investment banker third business day preceding redemption cash outflow approximately million us dollars plus accrued interest expected redemption group revised carrying value notes take account changes amounts timings estimated cash flows revised carrying value notes december million us dollars million swiss francs increase carrying value million us dollars million swiss francs recorded within financing costs see note loss redemption effective interest rate notes redemption repurchase bonds notes redemption us dollardenominated notes due date february group redeemed notes principal million us dollars original issue amount plus accrued original issue discount effective interest rate notes months libor plus cash outflow million swiss francs gain loss recorded redemption partial early redemption us dollardenominated notes december group resolved exercise option call redemption portion us dollardenominated fixed rate notes due march group redeemed billion us dollars total principal amount billion us dollars notes march amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow million swiss francs plus accrued interest december group already revised carrying value notes take account changes amounts timings estimated cash flow increase carrying value million swiss francs recorded within financing costs additional loss million swiss francs incurred upon final settlement notes effective interest rate notes roche finance report roche group notes roche group consolidated financial statementspartial repurchase eurodenominated notes june group completed tender offer nominal amount million euros fixed rate notes due march total principal amount billion euros cash outflow million swiss francs plus accrued interest loss repurchase notes million swiss francs addition group terminated currency swaps used hedge foreign currency risk eurodenominated notes created additional loss million swiss francs reflecting change fair value hedging derivatives due changes interest rates total loss repurchase million swiss francs recorded within financing costs effective interest rate notes repurchased partial repurchase swiss francdenominated bonds november group completed tender offer nominal amount million swiss francs fixed rate bonds due march total principal amount billion swiss francs cash outflow million swiss francs plus accrued interest loss repurchase bonds million swiss francs effective interest rate bonds repurchased partial repurchase pound sterlingdenominated notes december group completed tender offer nominal amount million pounds sterling fixed rate notes due march total principal amount billion pounds sterling cash outflow million swiss francs plus accrued interest loss repurchase notes million swiss francs effective interest rate notes repurchased partial repurchase pound sterlingdenominated notes december group completed tender offer nominal amount million pounds sterling fixed rate notes due august total principal amount million pounds sterling cash outflow million swiss francs plus accrued interest loss repurchase notes million swiss francs effective interest rate notes repurchased cash flows issuance redemption repurchase bonds notes cash inflows issuance bonds notes millions chf european medium term note programme eurodenominated notes swiss francdenominated bonds total cash inflows issuance bonds notes cash outflows redemption repurchase bonds notes millions chf swiss francdenominated bonds european medium term note programme eurodenominated notes european medium term note programme pound sterlingdenominated notes us dollardenominated notes total cash outflows redemption repurchase bonds notes roche group notes roche group consolidated financial statements roche finance report collateral arrangements group entered various currency swaps certain nonus dollar debt instruments issued collateral agreements entered counterparties currency swaps mitigate counterparty risk fair value derivative instruments increased mainly due strengthening euro compared us dollar total billion swiss francs cash collateral delivered group year billion swiss francs delivered group collateral delivered recorded increase cash corresponding increase accrued liabilities carrying value accrued liabilities respect agreements december billion swiss francs december accrued liabilities billion swiss francs commercial paper roche holdings inc commercial paper program march roche holdings inc established commercial paper program issue billion us dollars unsecured commercial paper notes guaranteed roche holding ltd committed credit line billion euros available backstop line maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount million us dollars average interest rate outstanding amounts due various dates january movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december amounts due banks financial institutions amounts denominated various currencies notably chinese renminbi argentine pesos average interest rate amounts outstanding million swiss francs december due within one year roche finance report roche group notes roche group consolidated financial statements equity attributable roche shareholders changes equity attributable roche shareholders millions chf reserves share retained fair capital earnings value hedging translation total year ended december january net income recognised income statement availableforsale investments valuation gains losses taken equity transferred income statement sale impairment ncome taxes n oncontrolling interests cash flow hedges gains losses taken equity transferred income statement ncome taxes n oncontrolling interests currency translation foreign operations e xchange differences accumulated differences transferred income statement divestment n oncontrolling interests defined benefit postemployment plans actuarial gains losses limit asset recognition ncome taxes n oncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity instruments changes noncontrolling interests december entire losses transferred income statement million swiss francs reported financial income roche group notes roche group consolidated financial statements roche finance report changes equity attributable roche shareholders millions chf reserves share retained fair capital earnings value hedging translation total year ended december january net income recognised income statement availableforsale investments valuation gains losses taken equity transferred income statement sale impairment ncome taxes n oncontrolling interests cash flow hedges gains losses taken equity transferred income statement ncome taxes n oncontrolling interests currency translation foreign operations e xchange differences n oncontrolling interests defined benefit postemployment plans actuarial gains losses limit asset recognition ncome taxes n oncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity instruments changes noncontrolling interests december entire gains transferred income statement million swiss francs reported financial income group completed purchase noncontrolling interests genentech effective march based revised international accounting standard consolidated separate financial statements ias adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group time reduced billion swiss francs billion swiss francs allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacted groups net equity effect groups business dividend policy roche finance report roche group notes roche group consolidated financial statementsshare capital december authorised issued share capital roche holding ltd groups parent company consisted shares nominal value swiss franc preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool described note based information supplied group novartis ltd basel affiliates participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend swiss francs per share nonvoting equity securities swiss francs respect business year distribution holders outstanding shares nonvoting equity securities totalled million swiss francs million swiss francs recorded retained earnings board directors proposed dividends business year swiss francs per share nonvoting equity security approved would result total distribution shareholders million swiss francs subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities millions millions nonvoting equity securities derivative instruments total equity instruments recorded within equity original purchase cost details equity instruments held december shown table fair values disclosed information purposes equity instruments december supplementary information equivalent number non voting equity securities strike price market value millions maturity chf chf billions nonvoting equity securities derivative instruments feb sept total roche group notes roche group consolidated financial statements roche finance report nonvoting equity securities derivative instruments held groups potential conversion obligations may arise roche option plan roche stocksettled stock appreciation rights roche restricted stock unit plan see note mainly consist call options exercisable time maturity group holds none shares reserves fair value reserve fair value reserve represents cumulative net change fair value availableforsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs earnings per share nonvoting equity security basic earnings per share nonvoting equity security calculation basic earnings per share nonvoting equity security number shares nonvoting equity securities reduced weighted average number nonvoting equity securities held group period basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security calculation diluted earnings per share nonvoting equity security net income weighted average number shares nonvoting equity securities outstanding adjusted effects dilutive potential shares nonvoting equity securities potential dilutive effects arise employee stock option plans exercise outstanding vested employee stock options would dilutive effect exercise outstanding vested chugai stock options would dilutive effect net income chugai positive diluted earnings per share nonvoting equity security reflects potential impacts dilutive effects earnings per share figures roche finance report roche group notes roche group consolidated financial statementsdiluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement c hugai noncontrolling interests total net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations defined benefit postemployment plans comprehensive income net tax total comprehensive income dividends noncontrolling shareholders c hugai noncontrolling interests equity compensation plans net transactions equity instruments changes noncontrolling interests equity contribution noncontrolling interests december c hugai noncontrolling interests total noncontrolling interests roche group notes roche group consolidated financial statements roche finance report statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics businesses calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense ssociates f inancial income f inancing costs ncome taxes operating profit depreciation property plant equipment amortisation intangible assets impairment goodwill impairment intangible assets impairment property plant equipment impairment net assetsheldforsale operating expenses defined benefit postemployment plans operating expenses equitysettled equity compensation plans net income expense provisions bad debt expense inventory writedowns adjustments cash generated operations cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total roche finance report roche group notes roche group consolidated financial statementscash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity dividends paid millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai dividends noncontrolling shareholders dividend withholding tax total significant noncash transactions significant noncash transactions none risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part business planning controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management specifically described detail financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai roche group notes roche group consolidated financial statements roche finance report carrying value fair value financial assets millions chf carrying value asset class fvtpla available heldfor heldto loans line items notes forsale trading maturity receivables total fair value year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts three months bonds debentures hares ther investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total year ended december accounts receivable accrued interest income marketable securities money market instruments time accounts three months bonds debentures hares ther investments cash cash equivalents derivative financial instruments availableforsale investments heldtomaturity investments loans receivable longterm trade receivables financial current assets restricted cash longterm assets total fairvaluethroughprofitorloss roche finance report roche group notes roche group consolidated financial statementsthe table analyses financial instruments carried fair value valuation method different levels defined follows level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial assets liabilities december millions chf level level level total financial assets recognised fair value marketable securities money market instruments time accounts three months bonds debentures hares derivative financial instruments availableforsale investments total financial liabilities recognised fair value derivative financial instruments total fair value hierarchy financial assets liabilities december millions chf level level level total financial assets recognised fair value marketable securities money market instruments time accounts three months bonds debentures hares derivative financial instruments availableforsale investments total financial liabilities recognised fair value derivative financial instruments total availableforsale investments exclude equity securities held cost million swiss francs million swiss francs carried fair value see note december level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments unquoted shares significant transfers level level vice versa december group financial assets classified level roche group notes roche group consolidated financial statements roche finance report credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets trade receivables subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective management trade receivables sustain growth profitability group optimising asset utilisation whilst maintaining risks acceptable level except noted significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties additionally group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held loans receivables none december groups combined trade accounts receivable balance three us national wholesale distributors amerisourcebergen corp cardinal health inc mckesson corp equivalent billion swiss francs representing groups consolidated trade accounts receivable billion swiss francs representing december group trade receivables billion swiss francs since beginning increasing financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries trade receivables billion euros billion swiss francs public customers countries reduction billion euros december mainly due collections spain following montoro plan well increased factoring deals italy group uses different measures improve collections countries including intense communication customers factoring negotiations payments plans charging interest late payments legal action group also applying new commercial arrangements public hospitals greece portugal nature geographic location counterparties trade receivables overdue shown table include overdue balances us national wholesalers southern europe public customers described trade receivables overdue nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland european union rest europe north america latin america japan rest asia africa australia oceania total roche finance report roche group notes roche group consolidated financial statementscash marketable securities subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity cash shortterm time deposits subject rules limit groups exposure individual financial institutions within fixed income marketable securities group holds billion swiss francs government securities switzerland counterparties rating aa better exception argentina million swiss francs december rated b rating analysis cash fixed income marketable securities market values mchf total mchf total aaarange aarange arange bbbrange bbbrange total derivatives group signs netting collateral agreements isda international swaps derivatives association master agreement respective counterparties order mitigate counterparty risk derivative positions group entered derivative contracts third parties hedge foreign exchange risk arising bonds notes issued groups us affiliate roche holdings inc currencies us dollar total billion swiss francs cash collateral delivered group year billion swiss francs delivered group collateral agreements set cash acceptable collateral collateral received delivered december related derivative activities overdue assets financial assets past due impaired total billion swiss francs billion swiss francs analysis overdue impaired financial assets class millions chf total amount overdue month months months months year year ended december loans receivables year ended december loans receivables december significant financial assets whose terms renegotiated none liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time group liquidity reported senior management monthly basis roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements addition group unused committed credit lines various financial institutions totalling billion swiss francs billion swiss francs decline undiscounted financial liabilities shown table mainly due debt repayments interest paid roche group notes roche group consolidated financial statements roche finance report contractual maturity analysis financial liabilities millions chf total months months months years years years years years year ended december total debt trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities year ended december total debt trade payables accruals derivative financial instruments liabilities current noncurrent total financial liabilities total debt table shows undiscounted cash flows whereas carrying value consolidated balance sheet reflects discounted cash flows market risk market risk arises changing market prices groups financial assets financial liabilities market risk may affect group financial result value group equity group uses valueatrisk var measure impact market risk financial instruments roche defined var limits manage market risk var data reported monthly basis indicate value range within given financial instrument fluctuate preset probability result movements market prices var statistical measure implicitly assumes value changes recent past indicative value changes future var figures represent actual expected losses possible worstcase losses stated period var figures calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate longer holding periods increase probability higher value changes lead increased var figures actual future gains losses associated treasury activities may differ materially var analyses performed due inherent limitations associated predicting timing amount changes interest rates foreign currency exchange rates equity investment prices particularly periods high market volatilities furthermore var numbers include effect changes credit spreads roche finance report roche group notes roche group consolidated financial statementsmarket risk financial instruments millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate var decreased million swiss francs reflecting ageing debt repayment debt issued debt held amortised cost interest rate var sole metric economic fair value changes impact carrying value profit loss group foreign exchange var remained stable price risk arises mainly movements prices equity securities remained largely stable december group held equity securities market value billion swiss francs december billion swiss francs includes holdings biotechnology companies acquired context licensing transactions scientific collaborations foreign exchange risk group operates across world exposed movements foreign currencies affecting group financial result value groups equity foreign exchange risk arises amount local currency paid received transactions denominated foreign currencies may vary due changes exchange rates transaction exposures foreign currency denominated financial statements groups foreign subsidiaries may vary upon consolidation swiss francdenominated group financial statements translation exposures objective groups foreign exchange risk management activities preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group monitors transaction exposures daily basis net foreign exchange result corresponding var parameters reported monthly basis group uses forward contracts foreign exchange options cross currency swaps hedge transaction exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates interest rate risk interest rate risk arises movements interest rates could affect group financial result value group equity changes interest rates may cause variations interest income expense addition may affect market value certain financial assets liabilities hedging instruments primary objective groups interest rate management protect net interest result interest rate exposures corresponding var parameters reported monthly basis group may use forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments equity price risk reported var figure monthly basis senior management roche group notes roche group consolidated financial statements roche finance report impairment financial assets impairments loans receivables mainly due increase expected nonrecoverability trade receivables writedowns debt securities million swiss francs relate greek government bonds received exchange trade receivables impairment losses asset classes millions chf loans receivables availableforsale financial assets hares nvestments ebt securities total impairment losses capital group defines capital manages groups total capitalisation sum debt plus equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events group completed purchase noncontrolling interests genentech effective march consideration net tax effects approximately billion swiss francs based revised international accounting standard consolidated separate financial statements ias adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group reduced billion swiss francs billion swiss francs allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacts groups net equity effect groups business dividend policy capital monitored basis capitalisation calculated debt plus equity including noncontrolling interests reported senior management part groups regular internal management reporting groups capitalisation shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation group subject regulatory capital adequacy requirements known financial services industry group majority shareholding chugai see note chugai public company objectives policies processes managing capital determined local management roche finance report roche group notes roche group consolidated financial statements related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received remuneration totalling swiss francs swiss francs dr oeri received remuneration totalling swiss francs swiss francs transactions group individual members shareholder group subsidiaries associates listing major group subsidiaries associates included note transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates key management personnel total remuneration key management personnel million swiss francs million swiss francs million swiss francs members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees total remuneration board directors excluding chairman totalled million swiss francs million swiss francs million swiss francs chairman board directors members corporate executive committee roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee chairman board directors members corporate executive committee also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members corporate executive committee mr diggelmann dr hippe mr oday included table full calendar year joined cec similarly members corporate executive committee retiring part way year dr soriot dr hunziker included full calendar year left cec remuneration chairman board directors members corporate executive committee millions chf salaries including cashsettled bonus bonus stock awards social security costs pensions postemployment benefits equity compensation plans retirement awards employee benefits total roche group notes roche group consolidated financial statements roche finance report purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included financial statements roche holding ltd basel pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration chairman board directors members corporate executive committee ifrs basis see table deduct bonus stock awards ifrs basis equity compensation plans ifrs basis add back bonus stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration chairman board directors members corporate executive committee swiss legal basis chairman board directors members corporate executive committee bonus stock awards certain members corporate executive committee granted bonus stock awards lieu part cashsettled bonus financial year issued end april total fair value million swiss francs million swiss francs none number awards fair value per award calculated grant date roche longterm members corporate executive committee granted stocksettled stock appreciation rights ssars roche option plan rop restricted stock unit rsu awards ssars rop rsu awards ssars rop rsu awards roche connect contributions paid group respect chairman board directors members corporate executive committee totalled million swiss francs million swiss francs million swiss francs roche performance share plan members corporate executive committee targeted awards cycle awards cycle award result zero two nonvoting equity securities depending upon achievement performance targets transactions former members corporate executive committee pensions totalling million swiss francs paid group former corporate executive committee members million swiss francs million swiss francs postemployment benefit plans transactions group various postemployment defined benefit plans employees group described note roche finance report roche group notes roche group consolidated financial statements subsidiaries associates divestment subsidiaries effective may group sold wholly owned subsidiary roche vitamins inc rvi third party addition group completed sale following whollyowned subsidiaries connection operational excellence programme roche colorado corporation boulder colorado roche madison inc madison wisconsin roche kulmbach gmbh kulmbach germany lascona land company inc philippines total consideration received divestments million swiss francs consisted million swiss francs cash marketable securities fair value million swiss francs deferred cash consideration million swiss francs received total gain loss divestments shown table gain loss divestment subsidiaries millions chf consideration net assets disposed property plant equipment g oodwill p rovisions c ash net assets accumulated currency translation adjustments total net assets disposed transaction costs provisions accruals residual obligations retained roche group gain loss divestment reported global restructuring plans roche pharmaceuticals operating segment general administration costs corporate operating segment listed companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo isin jp market capitalisation jpy roche group notes roche group consolidated financial statements roche finance report nonlisted companies share capital equity interest country company city millions algeria roche algerie spa bab ezzouar dzd argentina productos roche sa qumica e industrial buenos aires ars vanguardia en productos farmacuticos vanprofarma sa buenos aires ars australia roche diagnostics australia pty limited castle hill aud roche products pty limited dee aud austria roche austria gmbh vienna eur roche diagnostics gmbh vienna eur roche diagnostics graz gmbh graz eur belgium nv roche sa brussels eur roche diagnostics belgium sa brussels eur bermuda chemical manufacturing trading company limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd syntex pharmaceuticals international ltd hamilton usd bosniaherzegovina roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn canada chempharm limited toronto cad hoffmannla roche limited toronto cad sapac corporation ltd st john cad chile roche chile limitada santiago de chile clp china roche china holding ltd shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai limited shanghai usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche servicios sa heredia usd croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche hvidovre dkk roche diagnostics hvidovre dkk dominican republic productos roche dominicana sa santo domingo dop ecuador roche ecuador sa quito usd el salvador productos roche el salvador sa san salvador svc estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france institut roche de recherche et mdecine translationnelle sas boulognebillancourt cedex eur roche diagnostics france sas meylan eur roche sas boulognebillancourt cedex eur ventana medical systems sas illkirch eur georgia roche georgia llc tbilisi gel germany galenus mannheim gmbh mannheim eur nimblegen systems gmbh pleiskirchen eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen dem roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche mtm laboratories ag heidelberg eur roche pharma ag grenzachwyhlen eur roche pvt gmbh waiblingen eur swisslab gmbh berlin eur verum diagnostica gmbh munich eur roche finance report roche group notes roche group consolidated financial statementsshare capital equity interest country company city millions greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sa guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diagnostics india pvt ltd mumbai inr roche products india pvt ltd mumbai inr indonesia pt roche indonesia jakarta idr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd petach tikva ils italy roche diagnostics spa milan eur roche spa milan eur japan roche diagnostics kk tokyo jpy latvia roche latvija sia riga lvl lithuania uab roche lietuva vilnius lit malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd kuala lumpur myr syntex pharmaceuticals sdn bhd kuala lumpur myr mauritius roche products mauritius limited quatre bornes mur mexico productos roche sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn morocco roche sa casablanca mad netherlands roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche products limited lagos ngn norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd panama productos roche panam sa panama city pab productos roche interamericana sa panama city usd roche products inc panama city usd syntex puerto rico inc panama city usd peru productos roche qumica farmacutica sa lima pen philippines roche philippines inc taguig city php poland roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico roche operations ltd ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diagnostics rus moscow rub roche moscow ltd moscow rub serbia roche doo beograd belgrade eur singapore roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche doo pharmaceutical company ljubljana eur south africa roche products proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw roche group notes roche group consolidated financial statements roche finance report share capital equity interest country company city millions spain andreu roche sa madrid eur roche diagnostics sl barcelona eur roche farma sa madrid eur syntex roche sa madrid eur sri lanka roche products colombo private limited colombo lkr sweden roche ab stockholm sek roche diagnostics scandinavia ab bromma sek switzerland f hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche diabetes care ag burgdorf chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd steinhausen chf roche finance ltd basel chf roche forum buonas ag buonas chf roche glycart ag schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb turkey roche diagnostik sistemleri ticaret istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev usd united arab emirates roche diagnostics middle east fzco dubai aed roche middle east fzco dubai aed united kingdom piramed limited welwyn garden city gbp roche diagnostics ltd burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp united states life sciences corporation branford usd alios biopharma inc south san francisco usd anadys pharmaceuticals inc south san francisco usd bioveris corporation indianapolis usd genentech inc south san francisco usd genentech usa inc south san francisco usd hoffmannla roche inc nutley usd biofire diagnostics inc salt lake city usd igen international inc pleasanton usd marcadia biotech inc nutley usd roche carolina inc florence usd roche diagnostics corporation indianapolis usd roche diagnostics operations inc indianapolis usd roche holdings inc south san francisco usd roche insulin delivery systems inc fishers usd roche laboratories inc nutley usd roche molecular systems inc pleasanton usd roche nimblegen iceland llc reykjavik usd roche nimblegen inc madison usd roche tcrc inc nutley usd spring bioscience corp pleasanton usd ventana medical systems inc tucson usd uruguay roche international ltd montevideo branch hamilton uyu venezuela productos roche sa caracas vef vietnam roche diagnostics vietnam co ltd ho chi minh city usd share capital less local currency units roche finance report roche group notes roche group consolidated financial statementsreport roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set pages franz b humer alan hippe chairman board directors chief financial officer basel january roche group report roche management internal control financial reporting roche finance report report statutory auditor consolidated financial statements report statutory auditor consolidated financial statements annual general meeting roche holding ltd basel statutory auditor audited accompanying consolidated financial statements roche holding ltd comprise income statement statement comprehensive income balance sheet statement cash flows statement changes equity notes pages year ended december board directors responsibility board directors responsible preparation fair presentation consolidated financial statements accordance international financial reporting standards ifrs requirements swiss law responsibility includes designing implementing maintaining internal control system relevant preparation fair presentation consolidated financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion consolidated financial statements based audit conducted audit accordance swiss law swiss auditing standards international standards auditing standards require plan perform audit obtain reasonable assurance whether consolidated financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures consolidated financial statements procedures selected depend auditors judgement including assessment risks material misstatement consolidated financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation fair presentation consolidated financial statements order design audit procedures appropriate circumstances audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation consolidated financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion consolidated financial statements year ended december give true fair view financial position results operations cash flows accordance international financial reporting standards ifrs comply swiss law roche finance report roche group report statutory auditor consolidated financial statementsreport legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag ian starkey franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche group report statutory auditor consolidated financial statements roche finance report report independent auditor internal control financial reporting report independent auditor internal control financial reporting annual general meeting roche holding ltd basel examined roche groups system internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting responsibility express opinion companys internal control financial reporting based examination entitys internal control financial reporting process effected entitys board directors management personnel designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements conducted examination accordance international standard assurance engagements isae standard requires plan perform examination obtain reasonable assurance whether effective internal control financial reporting maintained material respects examination included obtaining understanding internal control financial reporting testing evaluating design operating effectiveness internal control performing procedures considered necessary circumstances believe examination provides reasonable basis opinion inherent limitations internal control financial reporting including possibility management override controls misstatements due error fraud may occur detected also projections evaluation internal control financial reporting future periods subject risk internal control may become inadequate changes conditions degree compliance policies procedures may deteriorate roche finance report roche group report independent auditor internal control financial reportingin opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg ag ian starkey franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche group report independent auditor internal control financial reporting roche finance report multiyear overview supplementary information multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity noncontrolling interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards dividend proposed board directors applied retrospectively roche finance report roche group multiyear overview supplementary informationmultiyear overview supplementary information multiyear overview statistics reported statement income millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income equity attributable roche shareholders research development sales current ratio equity noncontrolling interests total assets sales per employee thousands chf data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards dividend proposed board directors applied retrospectively roche group multiyear overview supplementary information roche finance report sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report roche group multiyear overview supplementary informationadditions property plant equipment division millions chf pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland european union germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche group multiyear overview supplementary information roche finance report supplementary core results eps information groups basic diluted earnings per share information given note annual financial statements pages group expanded presentation core results previously core eps shown full income statement group operating results divisions shown ifrs core basis allows transparent assessment actual results underlying performance business core results concept used internal management business based ifrs results following adjustments global restructuring plans see note excluded amortisation impairment intangible assets see note impairment goodwill see note excluded acquisition accounting onetime impacts alliance arrangements business combinations see financial review excluded discontinued operations currently none would excluded legal environmental expenses see financial review excluded global issues outside healthcare sector beyond groups control excluded includes directly attributable costs earthquake occurred japan march see note items material onetime treasury items major debt restructurings settlement pension plans currently none would excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial review roche finance report roche group multiyear overview supplementary informationcore results reconciliation millions chf alliances normali global intangibles business legal sation restruc amorti intangibles combi environ global ecp tax ifrs turing sation impairment nations mental issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable r oche shareholders n oncontrolling interests core results reconciliation millions chf alliances normali global intangibles business legal sation restruc amorti intangibles combi environ global ecp tax ifrs turing sation impairment nations mental issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit associates financial income financing costs profit taxes income taxes net income attributable r oche shareholders n oncontrolling interests roche group multiyear overview supplementary information roche finance report divisional core results reconciliation millions chf alliances global intangibles business legal restruc amorti intangibles combi environ global ifrs turing sation impairment nations mental issues core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf alliances global intangibles business legal restruc amorti intangibles combi environ global ifrs turing sation impairment nations mental issues core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary informationcore eps core net income chf millions core net income attributable roche shareholders increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised net income used calculate diluted earnings per share per share information millions shares nonvoting equity securities weighted average number shares nonvoting equity securities issue adjustment assumed exercise equity compensation plans dilutive weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share core earnings per share diluted chf roche group multiyear overview supplementary information roche finance report supplementary operating free cash flow information divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets impairment net assetsheldforsale total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct net cash flow equitysettled equity compensation plans utilisation provisions proceeds disposals total operating profit cash adjustments ebitda core operating profit depreciation impairment property plant equipment core basis ebitda margin sales roche finance report roche group multiyear overview supplementary informationsupplementary balance sheet information net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions associates current income tax net assets deferred income tax net assets postemployment benefit net assets marketable securities cash cash equivalents debt net assets net working capital longterm net operating assets ther total net assets net operating assets balance sheet reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury roche group property plant equipment goodwill intangible assets inventories provisions associates current income tax net assets deferred income tax net assets postemployment benefit net assets marketable securities cash cash equivalents debt net assets net working capital longterm net operating assets ther total net assets roche group multiyear overview supplementary information roche finance report r oche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased four roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded united states overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january roche finance report roche group roche securitiesnumber shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number nonvoting equity securities genussscheine held total issue data per share nonvoting equity security chf earnings diluted equity attributable roche shareholders dividend c stock price shareb opening high low yearend stock price nonvoting equity security genussscheinb opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche group roche securities roche finance report roche holding ltd basel financial statements notes financial statements summary significant accounting policies r isk management e quity board executive remuneration contingent liabilities board executive shareholdings ignificant shareholders appropriation available earnings report statutory auditor financial statements financial statements income statement millions chf year ended december income income participations interest income loans group companies interest investment income guarantee fee income group companies income total income expenses financial expenses administration expenses expenses total expenses profit year taxes taxes net profit year roche holding ltd basel financial statements roche finance report balance sheet millions chf december december noncurrent assets participations longterm loans group companies total noncurrent assets current assets accounts receivable group companies accounts receivable marketable securities liquid funds total current assets total assets equity share capital nonvoting equity securities genussscheine pm pm general legal reserve free reserve special reserve available earnings balance brought forward previous year net profit year total equity noncurrent liabilities provisions total noncurrent liabilities current liabilities accounts payable group companies unrealised foreign currency gains liabilities total current liabilities total liabilities total equity liabilities pm pro memoria nonvoting equity securities nominal value roche finance report roche holding ltd basel financial statementsnotes financial statements summary significant accounting policies basis preparation financial statements financial statements roche holding ltd basel prepared accordance provisions swiss law participations major participations company listed note roche group annual financial statements valuation methods translation foreign currencies marketable securities reported lower cost market value assets including participations reported cost less appropriate writedowns assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except participations translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred taxes tax charge includes corporate income capital taxes equity share capital previous year share capital amounts million swiss francs share capital consists bearer shares nominal value swiss franc included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates movement recognised amounts millions chf general legal special available share capital reserve free reserve reserve earnings total equity january n et income ividends december n et income ividends december n et income ividends transfer free reserve december roche holding ltd basel notes financial statements roche finance report contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december billion swiss francs billion swiss francs described note roche group annual financial statements pages significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri mr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool december based information supplied group shares shares owned novartis ltd basel including affiliates thereof participation risk management detailed disclosures regarding risk management required swiss law included roche group annual financial statements pages roche finance report roche holding ltd basel notes financial statements board executive remuneration board directors members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees remuneration members board directors thousands chf b gehrig hoffmann p baschera ji bell p bulcke b wm burns ljr de vink c franz b w frey julius ad levinson oeri w ruttenstorfer pr voser b b weder di mauro total remuneration board directors annual general meeting march mr frey dr ruttenstorfer stand reelection b annual general meeting march mr bulcke dr franz mr voser elected new members board directors remuneration dr levinson includes payments consulting work board membership genentech totalling thousand swiss francs thousand swiss francs chairman board directors dr franz b humer received remuneration shown table remuneration chairman board directors thousands chf annual salary including cashsettled bonus bonus stock awards pensions postemployment benefits equity compensation plans employee benefits total remuneration received social security costs total roche holding ltd basel notes financial statements roche finance report corporate executive committee members corporate executive committee cec roche holding ltd receive remuneration indirect benefits participate certain equity compensation plans shown table groups ceo dr severin schwan member corporate executive committee highest total remuneration remuneration also disclosed new members corporate executive committee mr diggelmann dr hippe mr oday included full calendar year joined cec similarly members corporate executive committee retiring part way year dr soriot dr hunziker included full calendar year left cec remuneration members corporate executive committee thousands chf total cec schwan total cec schwan total cec schwan annual salary including cashsettled bonus bonus stock awards pensions postemployment benefits equity compensation plans retirement awards employee benefits total remuneration received social security costs total bonus stock awards certain members corporate executive committee granted bonus stock awards lieu part cashsettled bonus financial year issued end april total fair value employee thousand swiss francs fair value awards employee calculated taking account period blocked years years number awards fair value per award calculated grant date employer contribution social security schemes pension plans group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members corporate executive committee equity compensation plans chairman board directors members corporate executive committee also participate certain equity compensation plans described terms vesting conditions awards disclosed note roche group annual financial statements fair values used roche group annual financial statements represent cost company grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions purposes remuneration disclosures values calculated based fair value employee receives taking account preliminary assessment completed performance conditions chairman board directors members corporate executive committee eligible participate roche connect programme enables employees make regular deductions salaries purchase nonvoting equity securities group contributes programme allows employees purchase nonvoting equity securities discount usually members corporate executive committee granted stocksettled stock appreciation rights ssars individual awards relating shown table fair value awards employees thousand swiss francs calculated using trinomial model american options roche finance report roche holding ltd basel notes financial statementsmembers corporate executive committee members senior management participate roche performance share plan psp group three overlapping threeyear psps target awards threeyear cycle defined beginning cycle awards considered form part employees remuneration three equal annual amounts threeyear cycle award result zero two nonvoting equity securities depending upon achievement performance targets discretion board directors individual awards relating shown table number awards calculated follows psp end cycle performance targets achieved accordingly participants received none originally targeted nonvoting equity securities psp one nonvoting equity security per award psp one nonvoting equity security per award resulting allocations multiplied nonvoting equity security price december swiss francs give fair value remuneration received employee remuneration equity compensation plans thousands chf roche connect ssar awards psp awards employer ssar ssar psp psp psp psp total contributions number fair value number number number fair value fair value total cec f schwan employee benefits include tax advisory costs incidental benefits transactions former members corporate executive committee pensions totalling million swiss francs paid group former corporate executive committee members million swiss francs million swiss francs roche holding ltd basel notes financial statements roche finance report board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members board directors nonvoting equity securities shares genussscheine fb humer b f b gehrig hoffmann c p baschera ji bell p bulcke wm burns b ljr de vink c franz julius e ad levinson oeri c pr voser b weder di mauro total include shares held shareholder group pooled voting rights b equity compensation awards roche option plan ssars roche performance share plan see c mr hoffmann dr oeri held ubs longshort certificates roche shares ro versus roche nonvoting equity securities genussscheine rog mr de vink held roche american depositary receipts adrs e close relatives dame deanne julius held roche nonvoting equity securities genussscheine f dr humer held rogtpk trackerplus certificates zrcher kantonalbank underlying roche nonvoting equity securities genussscheine rog roche finance report roche holding ltd basel notes financial statementscorporate executive committee members corporate executive committee persons closely associated held shares nonvoting equity securities shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan b ayyoubi r diggelmann na na hippe ga keller c oday p soriot na na total equity compensation awards roche option plan ssars roche performance share plan b close relatives dr schwan held roche nonvoting equity securities genussscheine c close relatives dr keller held roche shares roche shares december chairman board directors mr burns members corporate executive committee held roche option plan awards rops stocksettled stock appreciation rights ssars shown table awards held dr humer current chairman board directors mr burns current member board directors issued previous capacities members corporate executive committee terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included business report part annual report pages rops ssars awards held december year issue total schwan ayyoubi r diggelmann hippe ga keller oday total cec fb humer wm burns total strike price chf b expiry date mar feb feb feb jan b feb feb dr hippes awards strike price chf expire april b mr diggelmanns awards strike price chf expire july roche holding ltd basel notes financial statements roche finance report december members corporate executive committee shown table held psp awards psp performance cycles terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report pages business report part annual report award result zero two nonvoting equity securities depending upon achievement performance targets discretion board directors end cycle performance targets achieved accordingly participants received none originally targeted nonvoting equity securities total target number awards outstanding performance cycles december shown table roche performance share plan awards held december psp psp schwan ayyoubi r diggelmann hippe ga keller oday total cec allocation date feb feb december chairman board directors mr burns members corporate executive committee time held total stocksettled stock appreciation rights outstanding total awards granted roche performance share plan roche finance report roche holding ltd basel notes financial statementsappropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year transfer free reserve total appropriation available earnings carried forward account roche holding ltd basel appropriation available earnings roche finance report report statutory auditor financial statements report statutory auditor financial statements annual general meeting roche holding ltd basel statutory auditor audited accompanying financial statements roche holding ltd comprise income statement balance sheet notes pages year ended december board directors responsibility board directors responsible preparation financial statements accordance requirements swiss law companys articles incorporation responsibility includes designing implementing maintaining internal control system relevant preparation financial statements free material misstatement whether due fraud error board directors responsible selecting applying appropriate accounting policies making accounting estimates reasonable circumstances auditors responsibility responsibility express opinion financial statements based audit conducted audit accordance swiss law swiss auditing standards standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit involves performing procedures obtain audit evidence amounts disclosures financial statements procedures selected depend auditors judgement including assessment risks material misstatement financial statements whether due fraud error making risk assessments auditor considers internal control system relevant entitys preparation financial statements order design audit procedures appropriate circumstances purpose expressing opinion effectiveness entitys internal control system audit also includes evaluating appropriateness accounting policies used reasonableness accounting estimates made well evaluating overall presentation financial statements believe audit evidence obtained sufficient appropriate provide basis audit opinion opinion opinion financial statements year ended december comply swiss law companys articles incorporation roche finance report roche holding ltd basel report statutory auditor financial statementsreport legal requirements confirm meet legal requirements licensing according auditor oversight act aoa independence article co article aoa circumstances incompatible independence accordance article paragraph item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag ian starkey franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche holding ltd basel report statutory auditor financial statements roche finance report published cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking statements tel forwardlooking statements may identi fied words believes expects anticipates projects intends fax seeks estimates future similar expressions discussion among things strategy goals plans media office intentions various factors may cause actual results differ group communications materially future reflected forwardlooking basel switzerland statements contained annual report among others tel pricing product initiatives competitors legislative fax regulatory developments economic conditions delay inability obtaining regulatory approvals bringing products market fluctuations currency exchange rates general investor relations financial market conditions uncertainties discovery basel switzerland development marketing new products new uses tel existing products including without limitation negative results fax clinical trials research projects unexpected side effects pipeline marketed products increased government website pricing pressures interruptions production loss wwwrochecom inability obtain adequate protection intellectual property rights litigation loss key executives employees adverse publicity news coverage order publications tel statement regarding earnings per share growth profit fax forecast interpreted mean roches email baselwebmasterrochecom earnings earnings per share subsequent period necessarily match exceed historical published earnings next annual general meeting earnings per share roche march trademarks mentioned enjoy legal protection roche finance report published german english case doubt differences interpretation english version shall prevail german text printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communicationse roche finance report f hoffmannla roche ltd finance report basel switzerland trademarks legally protected wwwrochecom